Use of non-false transmission phase determination techniques and allele balance combinations to improve CNV detection
The method corrects allele balance signals through phase alignment and combined read depth and allele balance signals to enhance CNV detection accuracy, addressing noise and distortion issues in current detection methods, facilitating precise disease diagnosis and chromosomal instability assessment.
Patent Information
- Application Number
- JP2026197875
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-30
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-19
AI Technical Summary
Current methods for detecting copy number variants (CNVs) are challenged by noise from mixed normal and abnormal tissues, limited dynamic range in sequencing data, and non-uniform amplification, leading to inaccurate detection of chromosomal deletions and duplications.
A method for correcting allele balance signals using non-error propagation techniques, involving phase alignment of genetic codes from multiple sets of phases, and combining read depth signals with allele balance signals to enhance detection accuracy.
Improves the accuracy of detecting CNVs by reducing noise and distortion, enabling precise diagnosis of diseases such as cancer and fetal conditions, and identifying aneuploidy and chromosomal instability.
Smart Images

Figure 2026182915000022 
Figure 2026182915000023 
Figure 2026182915000024
Abstract
Description
Background Art
[0001] Cross-reference to Related Applications This application claims the benefit of U.S. Provisional Application No. 63 / 107,464, filed on October 30, 2020 the entire contents of which are incorporated herein by reference.
[0002] Background Copy number variants (CNVs) can be important indicators of disease and disease progression. CNVs have been identified as a major cause of structural variation in the genome, typically including both sequence duplications and deletions ranging in length from 1 kb to 20 Mb. Deletions and duplications of chromosomal segments or entire chromosomes are associated with various conditions such as susceptibility or resistance to diseases. However, methods for identifying CNVs remain challenging and are complicated by multiple issues. In some instances, normal tissue and abnormal tissue (comprising one or more CNVs) are mixed together, generating noise that interferes with the detection of one or more CNVs. In addition, available sequencing data may have a limited dynamic range. Furthermore, non-uniform amplification resulting from resampling bias can lead to distorted variant allele balance.
[0003] Accordingly, there is a need for more accurate detection of deletions and duplications of chromosomal segments or entire chromosomes that comprise CNVs There is a need for improved methods for accurate detection. Preferably, these methods can be used to more accurately diagnose diseases such as cancer or CNVs in a fetus during pregnancy, or an increased risk of a disease for accurate diagnosis.
Summary of the Invention
[0004] Summary According to one aspect of the present invention, a method for correcting an allele balance signal for a chromosomal segment is disclosed herein. This method can be at least partially phased This includes obtaining a reference genetic code having at least two sets of phases. The molecule has one or more variants of the subject of interest. This method further involves the genetic material From sequencing performed on the sample, one or more variants of the object of interest were identified. Obtaining gene balance signals and multiple sequences determined using non-error propagation techniques This includes obtaining leads for one or more variants of the subject of interest. It includes at least one of the following. Then the phase alignment of the two sets of phases is, Based on multiple reads, it is determined that they are the same phase or different phases, and the true alleles are determined. Balance signals are less based on the determined phase alignment of the two phase sets. By checking, correcting, or supplying the phase state of a variant of one of the objects of interest... It will be decided.
[0005] Non-error propagation techniques include structural capture, single-cell template chain sequencing, or (e.g., laser) This method may include isolation of chromosomes (via capture microanalysis or karyotype analysis). This may include performing non-false propagation techniques to obtain the allele. This may include sequencing a sample of genetic material to obtain a Lance signal. .
[0006] Allele balance signals and multiple reads can originate from the same sample of genetic material. The sample may be a bodily fluid sample (e.g., blood sample, saliva sample) or a tissue biopsy sample. Alleles: Genetic balance signals and multiple reads can originate from the same cell population. The child balance signal is derived from multiple reads originating from extracellular DNA and cellular DNA. Cellular DNA can be obtained from cells found in bodily fluids (e.g., blood or saliva).
[0007] The reference genetic code is used in sequencing to generate allele balance signals. It can originate from the reference genetic code, at least in part, from the allele balance signal. Sequence determination of normal tissue in the subject, sequence determination of germline tissue in the subject, Alternatively, it may be derived from the sequencing of genetic material from one or more genetically related individuals of the subject. One or more close relatives may be the subject's mother and / or father. The reference genetic code is: It may, at least in part, be derived from germline sequencing of one or a genetically closely related individual.
[0008] The reference genetic code is derived, at least in part, from the whole-genome shotgun sequencing of the subject. It is possible. Allele balance signals can originate from whole-genome shotgun sequencing. In either case, whole-genome shotgun sequencing is performed on bodily fluid samples (e.g., blood samples or This can be performed on extracellular DNA in saliva samples. Non-error propagation techniques are used for single-cell sequencing. This may include determination. This method involves taking a sample of genetic material from which the allele balance signal originates. To take and / or to collect samples of genetic material from multiple reads. This may further include:
[0009] Correcting allele balance data is at least partially phase-determined. This may include correcting switch errors in the genetic code. Allele balance signals The numbers are approximately 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 750,000, and 10 0 million, approximately 50 million or approximately 100 million, at least approximately 50,000, at least approximately 100,000, at least also about 200,000, at least about 300,000, at least about 400,000, at least about 500,000, at least also about 750,000, at least about 1,000,000, at least about 50,000,000 or at least about 100,000,000 or about 50,000 or less, about 100,000 or less, about 200,000 or less, about 300,000 or less, about 400,000 or less, about 500 ,000 or less, about 750,000 or less, about 1,000,000 or less, about 50,000,000 or less or about 100,000,000 or less base pairs can be averaged across a plurality of binned variants within the region. Allelic bal ance can be averaged across one or more haplotype blocks. One or more the plurality of haplotype blocks can be those determined by dilution pool sequencing . The allelic balance signal can be derived from the same sequencing that was used to determine one or more haplotype blocks . The allelic balance signa can be filtered for a minimum read depth, such as a minimum read depth of, for example, 5, 10, 15, 20 or 25 reads .
[0010] The two sets of phases can be adjacent sets of phases within a reference genetic code. For example, adjacent each of the sets of phases can comprise a variant of interest that is no more than about 1,000, about 5,000, about 10,000, about 50,000, about 100,000, about 5,000,000, about 1,000,000, about 5,000,000, about 10 ,000,000, about 50,000,000, about 100,000,000 or about 250,000,000 base pairs away from the variant of interest in the other The plurality of reads can be filtered for reads comprising at least 2, 3, 4 or 5 of the variants of interest from each of the two sets of phases . can be.
[0011] Non-error propagation techniques can specifically include chromosome conformation capture. Chromosome conformation capture The technology can be Hi-C. Determining phase alignment based on multiple leads. The majority of the reads relate to the estimated phase state alignment between two sets of phases. This may involve determining whether the two phases match or not. The estimated phase state alignment between sets is at least partial phase state of the reference genetic code. Determining phase alignment based on multiple leads, which can be based on the state, is possible for multiple leads. The amount of agreement or disagreement observed between two sets of phases from the same source is not necessarily a result of chance. This may include determining or estimating the rate. The probability is, optionally, that the observed fragments match or This could be a binomial probability, assuming that the probability of disagreement is equal.
[0012] This method may further include using a corrected allele balance signal to determine the ploidy status of a chromosomal segment. For example, determining the ploidy status could involve calling a copy number variant (CNV).
[0013] According to another aspect of the present invention, a method for determining the ploidy status of a chromosome segment is provided. Disclosed in the specification, this method involves one or more variants within a chromosomal segment. Obtain the read depth signal for the first set; and 1 within the chromosomal segment Obtain an allele balance signal for a second set of one or more variants. to determine the ploidy status of a chromosomal segment, and allele balance signals This includes using the lead depth signal in combination with the lead.
[0014] Determining the ploidy status of a chromosomal segment indicates the presence of CNVs within the chromosomal segment. This may include deciding whether or not to do so. Obtaining the read depth signal is the read Mapping to at least one variant in the first normalized set for the total number of [variants] This may include obtaining the number of sequenced reads. Read depth signals and / or Alternatively, the allele balance signal is approximately 50,000, 100,000, 200,000, 300,000, and 400,000. Approximately 500,000, approximately 750,000, approximately 1,000,000, approximately 50,000,000, or approximately 100,0 At least approximately 100,000, at least approximately 200,000, at least approximately 300,000, at least approximately 400,000 At least approximately 500,000, at least approximately 750,000, at least approximately 1,000,000, at least approximately 500 0,000 or at least approximately 100 million or approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 30 400,000 or less, 500,000 or less, 750,000 or less, 1,000,000 or less, 50,000,000 or less Plain across multiple bin-divided variants in a region of less than or approximately 100 million base pairs. It can be equalized. The read depth signal and / or allele balance signal are 1 It can be averaged across one or more haplotype blocks. The type block may be determined by dilution pool sequencing. Depth signals and allele balance signals are observed across the same binned region. It can be averaged out.
[0015] Using read depth signals in combination with allele balance signals is possible. The read depth signal exceeds the read depth threshold, and the allele balance signal is opposite. If the gene balance threshold is exceeded, or if the read depth signal exceeds the read depth threshold, If it does not exceed the threshold, and the allele balance signal does not exceed the allele balance threshold, This may include making a positive or negative determination. Read depth signals are used in allele analysis. When used in combination with Lance signaling, it enables the depth signaling and alleles of the reads. This may include integrating balanced signals into a single, unified signal. Read depth Integrating signaling and allele balance signals into a single, unified signal. This may include multiplying signals or adding signals together. The signals received were approximately 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, and 75,000. Ten thousand, approximately 1 million, approximately 50 million or approximately 100 million, at least approximately 50,000, at least approximately 100,000 , at least approximately 200,000, at least approximately 300,000, at least approximately 400,000, at least approximately 500,000 , at least approximately 750,000, at least approximately 1,000,000, at least approximately 50,000,000 or less All are approximately 100 million or less, approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less Below, approximately 500,000 or less, approximately 750,000 or less, approximately 1 million or less, approximately 50 million or less, or approximately 100 million or less It can be averaged across multiple binned variants within the region of the base pairs below. The resulting signals may be one or more determined by diluted pool sequencing. It can be averaged across several haplotype blocks. The integrated signal is read Depth signals and / or allele balance signals are averaged into multiple bins. It can be averaged out.
[0016] The first set of one or more variants can consist of only one variant. The first set of one or more variants is at least two, at least three, and 4, at least 5, at least 10, at least 20, at least 30, at least 4 0, at least 50, at least 60, at least 70, at least 80, at least 9 0, at least 100, at least 200, at least 300, at least 400, less at least 500, at least 600, at least 700, at least 800, at least 9 It may have 00 or at least 1,000 variants. The second set of to consists of only one variant. The set of 2 is at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600 , at least 700, at least 800, at least 900 or at least 1,000 It may have a number of variants. The first set of one or more variants is one or It may be identical to a second set of multiple variants.
[0017] To obtain read depth signals and / or allele balance signals. The benefits may include performing sequencing of read depth signals and alleles. Balance signals can originate from the same sequencing data. Read depth signals and / Alternatively, allele balance signals may consist of, for example, 5, 10, 15, 20, or 25 reads. You can filter by minimum read depth, such as the minimum read depth of the data.
[0018] The method described above is based on the depth signal and / or allele balance signal of the reads. Then, the individual probabilities of the exact determination of the polyploidy state, or the depth signals of the read Based on allele balance signals, the probability of accurately determining ploidy status is calculated. This may include calculations. Probabilities include, for example, true positive, false positive, true negative, and false The probability of one negative result can be measured. It is determined that at least one of the following is true. It can be determined that the combined probability of a false positive is less than the combined probability of each individual false positive, and the combined probability of a false negative is less than the combined probability of each individual false positive. The combined probability of a true positive is less than the combined probability of both individual false negatives. The combined probability of true negative is greater than both of the individual probabilities of true negative. .
[0019] The read depth signal may be canceled out against the first baseline signal, and / Alternatively, the allele balance signal may be offset by a second baseline signal. Each baseline signal corresponds to the second chromosome segment with a known ploidy state. This can be obtained based on the average signal. The second chromosome segment is used to determine the ploidy state. The chromosomal segment may be within the same chromosome. Read depth signal and / or pair The gene balance signal can be normalized to a measure of noise within the signal. The scale of ploidy is the known ploidy status across chromosomal segments where the ploidy status has been determined. The ploidy state of the second chromosome segment is different from that of the second chromosome segment, which has the second chromosome segment having This involves a third chromosome segment having a known ploidy state of interest, or staining. This can be the standard deviation or variance of the signal across the entire body. The variances within the allele balance signal are 100, 90, 80, and 7 in relation to each other. 0, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1.9, It can be within 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, or 1.1 times. Using read depth signals in combination with allele balance signals is possible. , false positive rate and / or false negative rate obtained using one or both signals individually Compared to that, the false positive rate and / or false negative rate are at least about twice, at least about three times, At least approximately 4 times, at least approximately 5 times, at least approximately 6 times, at least approximately 7 times, and at least Also about 8 times, at least about 9 times, at least about 10 times, at least about 20 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, at least Approximately 150 times, at least approximately 200 times, at least approximately 250 times, or at least approximately 500 times This can lead to a decrease.
[0020] Using read depth signals in combination with allele balance signals is possible. This may include selecting read depth thresholds and allele balance thresholds. Each value is known to indicate the ploidy state (e.g., aneuploidy) of the object of interest. It is calculated as half the average value of each signal averaged over the variants. Obtain. Use the read depth signal in combination with the allele balance signal. This may include selecting an integrated signal threshold. The integrated signal threshold is related Among several variants known to exhibit polyploidy (e.g., aneuploidy) in the cardiac object It can be calculated as half the average value of the averaged and integrated signals.
[0021] This method may result in aneuploidy of one or more chromosomes being detected.
[0022] This method can result in euploidy of all chromosomes detected and analyzed. The method may result in the addition and / or deletion of the detected chromosomal segment. The law results in identified CNVs.
[0023] Obtaining allele balance signals is described elsewhere in this specification. By implementing any one of the above methods for making such corrections, the original opposition This may include correcting gene balance signals.
[0024] According to another aspect of the present invention, any of the above methods differs with respect to the chromosomal segment. A signal indicating a ploidy state derived from a sample containing a population of cells with a certain copy number (for example) This may include obtaining allele balance signals or read depth signals. Some cells in a population of cells may exhibit aneuploidy, while others do not. This is possible. The signal may originate from a sample containing one or more tumor cells. The sample is , and may further include non-tumor cells.
[0025] According to another aspect of the present invention, any of the above methods is derived from extracellular DNA ploidy A signal indicating the state (e.g., allele balance signal or read depth signal) This may include obtaining extracellular DNA, which is also extracellular fetal DNA (cffDNA). This could be circulating tumor DNA (ctDNA).
[0026] According to another aspect of the present invention, any of the above methods is a ploidy state from an embryo or fetus. A signal indicating this (e.g., allele balance signal or read depth signal) This may include obtaining the embryo. The embryo is present in vitro, for example, before implantation in the uterus. It could be a developing embryo.
[0027] According to another aspect of the present invention, a method for detecting chromosomal instability in tumor DNA is described herein. This is disclosed. This method involves one or more chromosomal segments in a sample of genetic material. The ploidy state is determined according to any one of the aforementioned methods for determining the ploidy state. This includes the fact that the genetic material sample is known to be, at least partially, a tumor cell. DNA originating from one or more cells suspected to be tumor cells It originates from. Identifying aneuploidy status in one or more chromosomal segments is at least It is also used to demonstrate chromosomal instability in some tumor cells.
[0028] The sample may come from a person diagnosed with cancer or suspected of having cancer. It may contain ring tumor DNA. In order to establish the reference genetic code, the genetic material obtained is from the subject. Sequencing of normal tissue (e.g., germline tissue) or tumor tissue may be used. The law stipulates that, based on whether chromosomal instability is demonstrated, the genetic material obtained therefrom This may further include treating one or more cells or targets for cancer. In cases where chromosomal instability is observed, poly-ADP-ribose polymerase (PARP) is used. Administer one or more inhibitors and / or platinum-based chemotherapeutic agents to cells or subjects. This may include doing so.
[0029] In another aspect of the present invention, a method for detecting de novo copy number variants (CNVs) in a subject is disclosed herein. This method comprises determining the ploidy status according to any one of the aforementioned methods for determining the ploidy status of a chromosomal segment. The parents of the subject are euploid with respect to the chromosomal segment. De novo aneuploids (e.g., CNVs) can be identified in the chromosomal segment of the subject by carrying out this method.
[0030] The determination of ploidy status is performed on one or more genetically related individuals of the subject. This may include comparing it with a reference genetic code derived from the sequence determination.
[0031] One or more genetic relatives may be the mother and / or father of the subject. (Sequencing) The method of providing multiple leads is to provide multiple leads according to any one of the aforementioned methods for providing multiple leads. To achieve this, non-error propagation techniques may be used. Sequencing is performed on cellular DNA. This method can determine whether the mother or father in question is the cause of aneuploidy. It may further include the following.
[0032] The subject may be an embryo. The method described above involves embryo biopsy, blastocoel fluid, or cell culture medium (in the culture medium). Signals indicating ploidy status (e.g., allele balance) derived from extracellular DNA. The method may include obtaining a signal (depth signal) of the signal or read. This may further include selecting embryos based on their absence or presence. Embryos are selected from multiple embryos. Selected embryos may be used for in vitro fertilization (IVF), disposed of, or It may be frozen.
[0033] The subject may be a fetus. The above method is derived from extracellular fetal DNA (cffDNA). Numerical state-indicating signals (e.g., allele balance signals or read depth signals) This may include obtaining a null. The method may include determining the aneuploidy (e.g., CNV). Treatment may include treating the fetus and / or mother based on the absence or presence of the fetus. This may include performing additional tests on the fetus, such as karyotype analysis. The procedure may also affect the pregnancy. This may include terminating the procedure. The action is related to the presence of detected aneuploidy (e.g., CNV). This may include administering prenatal treatment to the fetus for the disease.
[0034] According to another aspect of the present invention, a method for screening subjects for a disease is described herein. Disclosed. This method is based on the existence of one or more genetic variants associated with the disease. This includes determining whether or not one or more genetic variants exist. For other objects, perform any one of the above methods for determining the ploidy state. Therefore, the identified aneuploidy (e.g., CNV) and / or the same haplotype as the aneuploidy It contains SNPs that were present within the lock. SNPs are known to be associated with disease. That is possible.
[0035] CNVs and SNPs may be in linkage disequilibrium. One or more genes associated with the disease. Determining whether a target variant exists involves performing a sequence determination on the target. It may include. A portion of the genome containing one or more genetic variants (for example, The cells may be targeted for sequencing (via an ichrome array). The aforementioned methods may include one or more of these methods. Based at least partially on the genetic variant, polygene risk scores for the disease The method may include calculating (PRS). The method includes one or more genetic variants. Based at least partially on the presence or absence of one or more genes, or on one or more genes Based on PRS that is at least partially based on the target variant, the patient with the disease is diagnosed. The method may further include the presence or absence of one or more genetic variants. This may include treating an object based on its non-existence.
[0036] According to another aspect of the present invention, the phase of germline mosaic variants in a subject is determined. A method is disclosed herein. This method relates to a reference legacy having at least two sets of phases. This includes obtaining the transmitted code. Each set of phases is one or more variants of the one of interest. The reference genetic code has a phase that can be determined at least partially. This method is non-error. This further includes obtaining multiple sequenced reads using propagation techniques. Each read is , including at least one of one or more variants of the object of interest. The phase alignment of the lead is determined based on multiple leads, and whether they are in the same phase or different phases. Haplotypes that are determined to include chromosomal segments exhibiting aneuploidy (e.g., CNV) It is identified based on the determined phase alignment of two sets of phases.
[0037] The target group includes individuals diagnosed with or suspected of having a genetic disorder or condition associated with aneuploidy. It is possible that the subject may have been diagnosed with Noonan syndrome or rhasopathy. or may be suspected of having. The method described above applies to the identified haplotype. The method may further include screening gametes from the following: This may further include selecting gametes that do not have the identified haplotype. The law requires screening for haplotypes in embryos during preimplantation genetic testing. The method may include selecting embryos based on the absence or presence of aneuploidy. The embryos may be selected from multiple embryos. The method described above involves in vitro fertilization (IVF) of the selected embryos. ) to be used in, to dispose of selected embryos, or to freeze selected embryos. This may include: Singularity is any one of the above methods for determining ploidy status. It can be identified by performing this action. (Item 1) A method for correcting allele balance signals for chromosomal segments, Obtaining a reference genetic code comprising two sets of phases, each set of phases having one or more variants of interest, and optionally, the reference genetic code having at least partially determined phases; Obtaining the allele balance signal for one or more variants of interest from sequencing performed on a sample of genetic material; Obtaining a plurality of sequenced reads using a non-error propagation technique, wherein each read includes at least one of one or more variants of the subject of interest; Based on the aforementioned multiple leads, the phase alignment of the two sets of phases is determined to be either the same phase or different phases; Based on the determined phase alignment of the two phase sets, the true allele balance signal is determined by confirming, correcting, or supplying the phase state of at least one variant of interest; Methods that include... (Item 2) The method according to item 1, wherein the non-error propagation technique includes capturing chromosome three-dimensional structure, single-cell template strand sequencing, or isolation of chromosomes (e.g., via laser-captured microscopy or karyotype). (Item 3) The method according to item 1 or 2, further comprising performing the non-fault propagation technique to obtain the aforementioned multiple leads. (Item 4) The method according to any one of items 1 to 3, wherein obtaining the allele balance signal includes performing the sequencing on a sample of the genetic material. (Item 5) The method according to any one of items 1 to 4, wherein the allele balance signal and the plurality of reads are obtained from the same sample of genetic material, optionally the sample being a bodily fluid sample (e.g., a blood sample, a saliva sample) or a tissue biopsy sample, and further optionally the allele balance signal and the plurality of reads are obtained from the same population of cells. (Item 6) The method according to any one of items 1 to 5, wherein the allele balance signal is obtained from extracellular DNA, the plurality of reads are obtained from cellular DNA, and optionally the cellular DNA is obtained from cells found in bodily fluids (e.g., blood or saliva). (Item 7) The method according to any one of items 1 to 6, wherein the reference genetic code is obtained from sequencing used to generate the allele balance signal. (Item 8) The method according to any one of items 1 to 7, wherein the reference genetic code is obtained, at least in part, from sequencing of normal tissue in the subject from which the allele balance signal is obtained. (Item 9) The method according to any one of items 1 to 8, wherein the reference genetic code is obtained, at least in part, from sequencing of germline tissue in the subject from which the allele balance signal is obtained. (Item 10) The method according to any one of items 1 to 9, wherein the reference genetic code is obtained, at least in part, from sequencing genetic material from one or more genetically related individuals of the subject from whom the allele balance signal is obtained. (Item 11) The method described in item 10, wherein one or more of the aforementioned close relatives are the mother and / or father. (Item 12) The method according to item 10 or 11, wherein the reference genetic code is obtained at least in part from germline sequencing of item 1 or a genetically related person. (Item 13) The aforementioned reference genetic code, at least partially, is used to obtain the allele balance signal. A method obtained from whole-genome shotgun sequencing of the subject, as described in any one of items 1 to 12. (Item 14) The method according to item 13, wherein the allele balance signal is obtained from the whole-genome shotgun sequencing. (Item 15) The method according to item 13 or 14, wherein the whole-genome shotgun sequencing is performed on extracellular DNA in a bodily fluid sample (e.g., a blood sample or a saliva sample). (Item 16) The method according to any one of items 1 to 15, wherein the non-error propagation technique includes single-cell sequencing. (Item 17) The method according to any one of items 1 to 16, further comprising taking a sample of the genetic material obtained therefrom, the allele balance signal. (Item 18) The method according to any one of items 1 to 17, further comprising taking samples of the genetic material obtained therefrom from the plurality of reads. (Item 19) The method according to any one of items 1 to 18, wherein correcting the allele balance data includes correcting a switch error in the at least partially phased reference genetic code. (Item 20) The method according to any one of items 1 to 19, wherein the allele balance signal is averaged over multiple binned variants within a region of at least about 50,000, at least about 100,000, at least about 200,000, at least about 300,000, at least about 400,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 50,000,000, or at least about 100 million base pairs. (Item 21) The method according to any one of items 1 to 20, wherein the allele balance signal is averaged across multiple binned variants within a region of approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less, approximately 500,000 or less, approximately 750,000 or less, approximately 1,000,000 or less, approximately 50,000,000 or less, or approximately 100 million or less base pairs. (Item 22) The method according to any one of items 1 to 21, wherein the allele balance is averaged across haplotype blocks. (Item 23) The method according to item 22, wherein the haplotype block is determined by diluted pool sequencing, and optionally the allele balance signal is obtained from the same sequencing. (Item 24) The method according to any one of items 1 to 23, wherein the allele balance signal is filtered for minimum read depth, and optionally the minimum read depth is 5, 10, 15, 20, or 25 reads. (Item 25) The method according to any one of items 1 to 24, wherein the two sets of phases are adjacent sets of phases in the reference genetic code. (Item 26) The method according to item 25, wherein each of the adjacent sets of phases contains a variant of interest that is not more than about 1,000, about 5,000, about 10,000, about 50,000, about 10 million, about 1 million, about 5 million, about 10 million, about 50 million, about 100 million, or about 250 million base pairs from the variant of interest in the other. (Item 27) The method according to any one of items 1 to 26, wherein the plurality of reads are filtered to include reads that contain at least two, three, four, or five variants of interest from each of the two sets of phases. (Item 28) The method according to item 2, wherein the non-error propagation technique includes chromosome three-dimensional structure capture, and optionally, the chromosome three-dimensional structure capture is Hi-C. (Item 29) Determining the phase alignment based on the plurality of reads includes determining whether the majority of the reads agree or disagree with respect to the estimated phase-state alignment between the two sets of phases, and optionally the estimated phase-state alignment is based on at least partial phase states of the reference genetic code, as described in item 28. (Item 30) The method according to item 28 or 29, wherein determining the phase alignment based on the plurality of reads includes determining or estimating the probability that the amount of agreement or mismatch observed between the two sets of phases from the plurality of reads is a result of chance. (Item 31) The method according to item 30, wherein the aforementioned probability is a binomial probability, and it is arbitrarily assumed that the observed fragments have an equal probability of being identical or non-identical. (Item 32) The method according to any one of items 1 to 31, further comprising using the corrected allele balance signal to determine the ploidy status of a chromosomal segment, and optionally, determining the ploidy status by calling a copy number variant (CNV). (Item 33) A method for determining the ploidy status of a chromosome segment, To obtain a read depth signal for a first set of one or more variants within the chromosomal segment; To obtain an allele balance signal for a second set of one or more variants within the chromosomal segment; To determine the ploidy state of the chromosome segment, the depth signal of the read is used in combination with the allele balance signal; Methods that include... (Item 34) The method according to item 33, wherein determining the ploidy status of the chromosomal segment is a means of determining whether or not a CNV is present within the chromosomal segment. (Item 35) The method according to item 33 or 34, wherein obtaining the depth signal of the reads includes obtaining the number of sequencing reads mapped to at least one of the variants in the first set, normalized to the total number of reads. (Item 36) The method according to any one of items 33 to 35, wherein the depth signal of the read is averaged over multiple binned variants within a region of at least about 50,000, at least about 100,000, at least about 200,000, at least about 300,000, at least about 400,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 50,000,000, or at least about 100 million base pairs. (Item 37) The depth signal of the aforementioned read is approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less, approximately 500,000 or less, approximately 750,000 or less, approximately 1,000,000 or less, approximately 50,000,000 or less. The method described in any one of items 33-36, which is averaged across multiple binned variants within a region of approximately 100 million base pairs or less. (Item 38) The method according to any one of items 33-37, wherein the depth signal of the read is averaged across the haplotype block. (Item 39) The method according to item 38, wherein the haplotype block is determined by diluted pool sequencing. (Item 40) The method according to any one of items 33 to 38, wherein the allele balance signal is averaged over multiple binned variants within a region of at least about 50,000, at least about 100,000, at least about 200,000, at least about 300,000, at least about 400,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 50,000,000, or at least about 100 million base pairs. (Item 41) The method according to any one of items 33 to 40, wherein the allele balance signal is averaged across multiple binned variants within a region of approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less, approximately 500,000 or less, approximately 750,000 or less, approximately 1,000,000 or less, approximately 50,000,000 or less base pairs. (Item 42) The method according to any one of items 33-41, wherein the allele balance signal is averaged across haplotype blocks. (Item 43) The method according to item 42, wherein the haplotype block is determined by diluted pool sequencing. (Item 44) The method according to any one of items 33 to 43, wherein the depth signal and the allele balance signal of the reads are averaged across the same binned region. (Item 45) The method according to any one of items 33 to 44, wherein using the depth signal of the read in combination with the allele balance signal makes a positive or negative determination only if the depth signal of the read exceeds the read depth threshold and the allele balance signal exceeds the allele balance threshold, or if the depth signal of the read does not exceed the read depth threshold and the allele balance signal does not exceed the allele balance threshold. (Item 46) The method according to any one of items 33 to 44, wherein using the depth of the read signal in combination with the allele balance signal comprises integrating the read depth signal and the allele balance signal into a single integrated signal. (Item 47) The method of item 46, wherein the depth signal and the allele balance signal of the reads are combined into a single integrated signal, which includes crossing the signals. (Item 48) The method according to item 46, wherein integrating the depth signal and the allele balance signal of the reads into a single combined signal is performed by adding the signals together. (Item 49) The aforementioned integrated signals are at least approximately 50,000, at least approximately 100,000, and at least approximately 2 The method described in any one of items 46-48, which is averaged over multiple binned variants within a region of 0,000, at least about 300,000, at least about 400,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 50,000,000, or at least about 100 million base pairs. (Item 50) The method according to any one of items 46 to 49, wherein the integrated signal is averaged over multiple binned variants within a region of approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less, approximately 500,000 or less, approximately 750,000 or less, approximately 1,000,000 or less, approximately 50,000,000 or less base pairs. (Item 51) The method according to any one of items 46-50, wherein the integrated signal is averaged across haplotype blocks. (Item 52) The method according to item 51, wherein the haplotype block is determined by diluted pool sequencing. (Item 53) The method according to any one of items 46 to 52, wherein the integrated signal is averaged across a plurality of bins in which the depth signal and / or the allele balance signal of the reads are averaged. (Item 54) The method according to any one of items 33 to 53, wherein the first set of the one or more variants consists of one variant. (Item 55) The method according to any one of items 33 to 53, wherein the first set of the one or more variants comprises at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 variants. (Item 56) The method according to any one of items 33 to 55, wherein the second set of the one or more variants consists of one variant. (Item 57) The method according to any one of items 33 to 53, wherein the second set of the one or more variants comprises at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 variants. (Item 58) The method according to any one of items 33 to 57, wherein the first set of the one or more variants is identical to the second set of the one or more variants. (Item 59) The method according to any one of items 33 to 58, wherein obtaining the depth signal of the read and / or obtaining the allele balance signal is performed, the method comprising sequencing. (Item 60) The method according to any one of items 33 to 59, wherein the depth signal and allele balance signal of the reads are derived from the same sequencing data. (Item 61) The method according to any one of items 33 to 60, wherein the depth signal and / or allele balance signal of the reads are filtered for a minimum read depth, wherein the minimum read depth is optionally 5, 10, 15, 20, or 25 reads. (Item 62) The method according to any one of items 33 to 61 further comprises calculating individual probabilities of an accurate determination of ploidy status based on the depth signal of the read and / or the allele balance signal, or calculating a combined probability of an accurate determination of ploidy status based on the depth signal of the read and the allele balance signal, wherein the probabilities measure the probability of one of the following: true positive, false positive, true negative, and false negative. (Item 63) At least one of the following is true: a) The combined probability of a false positive is less than the combined individual probability of a false positive. b) The combined probability of a false negative is less than the combined individual probability of a false negative. c) The joint probability of a true positive is greater than both of the individual probabilities of a true positive, and d) The binding probability of a true negative is greater than both of the individual probabilities of true negatives. The method described in item 62. (Item 64) The method according to any one of items 33 to 63, wherein the depth signal of the read is offset against a first baseline signal, and / or the allele balance signal is offset against a second baseline signal. (Item 65) The method according to item 64, wherein each baseline signal is based on the mean signal for a second chromosomal segment having a known ploidy state, and optionally, the second chromosomal segment having a known ploidy state is located on the same chromosome as the chromosomal segment whose ploidy state has been determined. (Item 66) The method according to any one of items 33 to 65, wherein the depth signal and / or the allele balance signal of the read are normalized to a measure of noise in the signal, and optionally the measure of noise is the standard deviation or variance of the signal over the chromosome segment in which the ploidy state is determined, over the second chromosome segment as described in item 65, over the third chromosome segment having a known ploidy state of interest different from the ploidy state of the second chromosome segment, or over the entire chromosome. (Item 67) The method according to any one of items 33 to 66, wherein the variance in the depth signal and the variance in the allele balance signal of the reads are within 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, or 1.1 times each other. (Item 68) The method according to any one of items 33 to 67, wherein using the depth signal of the read in combination with the allele balance signal results in a reduction of the false positive and / or false negative rates by at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 150, at least about 200, at least about 250, or at least about 500 compared to the false positive and / or false negative rates obtained by using one or both of the signals individually. (Item 69) Using the depth signal of the read in combination with the allele balance signal includes selecting the depth threshold and allele balance threshold of the read, and optionally the signal threshold is the mean value of each signal averaged over a plurality of variants known to represent the ploidy state (e.g., aneuploidy) of the subject of interest. Half, as described in any one of items 33-68. (Item 70) The method according to any one of items 33 to 69, wherein using the depth signal of the read in combination with the allele balance signal comprises selecting an integrated signal threshold, optionally, the integrated signal threshold being half the mean value of the integrated signal averaged over multiple variants known to exhibit a ploidy state (e.g., aneuploidy) of interest. (Item 71) The method according to any one of items 33 to 70, wherein the method results in aneuploidy of one or more chromosomes being detected. (Item 72) The method according to any one of items 33 to 70, wherein the method results in euploidy of all chromosomes that have been detected and analyzed. (Item 73) The method according to any one of items 33 to 72, wherein the method results in the addition and / or deletion of the detected chromosomal segment. (Item 74) The method according to any one of items 33 to 73, wherein the method results in an identified CNV. (Item 75) The method according to any one of items 33 to 74, wherein obtaining the allele balance signal includes correcting the original allele balance signal by performing the method according to any one of items 1 to 32. (Item 76) The method according to any one of items 1 to 75, wherein the method comprises obtaining a signal indicating ploidy status (e.g., an allele balance signal or a read depth signal) from a sample containing a population of cells having different copy numbers for the chromosome segment, and optionally, some cells being aneuploid and others not being aneuploid. (Item 77) The method according to any one of items 1 to 76, wherein the method comprises obtaining a signal indicating a ploidy state (e.g., the allele balance signal or the read depth signal) obtained from a sample containing one or more tumor cells. (Item 78) The method according to item 77, wherein the sample further comprises non-tumor cells. (Item 79) The method according to any one of items 1 to 78, comprising obtaining a signal indicating a ploidy state of the induced extracellular DNA (e.g., the allele balance signal or the read depth signal), wherein the extracellular DNA optionally includes extracellular fetal DNA (cffDNA) or circulating tumor DNA (ctDNA). (Item 80) The method according to any one of items 1 to 79, wherein the method optionally includes obtaining a signal indicating the ploidy state obtained from the embryo (e.g., the allele balance signal or the read depth signal) before implantation of the embryo in the uterus. (Item 81) The method according to any one of items 1 to 80, wherein the method comprises obtaining a signal indicating ploidy status obtained from a fetus (for example, the allele balance signal or the read depth signal). (Item 82) A method for detecting chromosomal instability in tumor DNA, Originating from one or more cells known or suspected to be tumor cells A method comprising determining the ploidy status of one or more chromosomal segments in a sample of genetic material obtained at least partially from DNA, the ploidy status of which is determined according to any one of items 32 to 81, wherein the identification of the aneuploidy status of the one or more chromosomal segments is used to indicate chromosomal instability in at least some tumor cells. (Item 83) The aforementioned sample originates from a subject who has been diagnosed with cancer or is suspected of having cancer, item The method described in 82. (Item 84) The method according to item 82 or 83, wherein the sample contains circulating tumor DNA. (Item 85) The method according to any one of items 82 to 84, wherein sequencing of normal tissue (e.g., germline tissue) from the subject from which the genetic material is obtained is used to establish a reference genetic code. (Item 86) The method according to any one of items 82 to 84, wherein sequencing of tumor tissue from the subject from which the genetic material is obtained is used to establish a reference genetic code. (Item 87) The method according to any one of items 82 to 86, further comprising treating the one or more cells or subjects from which the genetic material is derived for cancer, based on whether chromosomal instability is demonstrated. (Item 88) The method according to item 87, wherein the treatment comprises administering a poly-ADP-ribose polymerase (PARP) inhibitor to one or more cells or subjects if chromosomal instability is observed. (Item 89) The method according to item 87 or 88, wherein the treatment includes administering a platinum-based chemotherapeutic agent to one or more cells or subjects if chromosomal instability is observed. (Item 90) A method for detecting de novo copy number variants (CNVs) in a subject, comprising determining the ploidy status of a chromosomal segment according to any one of items 32 to 81, wherein the parent of the subject is euploid with respect to the chromosomal segment, and optionally, a de novo aneuploid (e.g., CNV) is identified in the chromosomal segment of the subject. (Item 91) The method according to item 90, wherein the determination of the ploidy state includes comparing the ploidy state with a reference genetic code obtained from sequencing performed on one or more genetic relatives of the subject. (Item 92) The method according to item 91, wherein the one or more genetic relatives are the mother and / or father. (Item 93) The method according to item 91 or 92, wherein the sequencing is performed using a non-error propagation technique to provide a plurality of reads according to any one of items 1 to 32. (Item 94) The method according to any one of items 91 to 93, wherein the sequencing is performed on cellular DNA. (Item 95) The method according to any one of items 90 to 94, further comprising determining whether the mother or father of the subject is the cause of aneuploidy. (Item 96) The method according to any one of items 90 to 95, wherein the subject is an embryo. (Item 97) The method according to item 96, comprising obtaining a signal indicating ploidy status (e.g., the allele balance signal or read depth signal) obtained from one or more of the following: embryo biopsy, blastocoel fluid, and cell culture medium. (Item 98) The method according to item 97, wherein the signal indicating the ploidy state is obtained from extracellular DNA in the culture medium. (Item 99) The method according to any one of items 96 to 98, further comprising selecting the embryos based on the absence or presence of aneuploidy, and optionally, selecting the embryos from a plurality of embryos. (Item 100) The method according to item 99, further comprising using the selected embryos for in vitro fertilization (IVF). (Item 101) The method according to item 99, further comprising disposing of the selected embryos. (Item 102) The method according to item 99, further comprising freezing the selected embryos. (Item 103) The method according to any one of items 90 to 94, wherein the subject is a fetus. (Item 104) The method according to item 103, comprising obtaining a signal indicating ploidy status derived from extracellular fetal DNA (cffDNA) (e.g., the allele balance signal or the read depth signal). (Item 105) The method according to item 103 or 104, further comprising treating the fetus and / or the mother based on the identified absence or presence of aneuploidy (e.g., CNV). (Item 106) The method according to item 105, wherein the procedure includes performing further tests on the fetus, and optionally, the further tests include karyotype analysis. (Item 107) The method described in item 105 or 106, wherein the procedure includes terminating the pregnancy. (Item 108) The method according to any one of items 105 to 107, wherein the treatment includes administering prenatal treatment to the fetus for a disease associated with the presence of detected aneuploidy (e.g., CNV). (Item 109) A method for screening subjects for a disease, A method for determining whether one or more genetic variants associated with the disease exist, wherein the one or more genetic variants include an aneuploidy (e.g., CNV) and / or a SNP located within the same haplotype block as the aneuploidy, identified by performing the method described in any one of items 32 to 81 on one or more other subjects, and optionally, the SNP is known to be associated with the disease. (Item 110) The method according to item 109, wherein one or more of the genetic variants include the aneuploidy. (Item 111) The method according to item 109 or 110, wherein the one or more genetic variants include the SNP. (Item 112) The method according to any one of items 109 to 111, wherein the CNV and SNP are in linkage disequilibrium. (Item 113) The method according to any one of items 109 to 112, wherein determining whether the one or more genetic variants associated with the disease are present comprises sequencing the subject, and optionally, a portion of the genome containing the one or more genetic variants is targeted (e.g., via a microarray). (Item 114) The method according to any one of items 109 to 113, further comprising calculating a polygene risk score (PRS) for the disease based at least partially on one or more of the aforementioned genetic variants. (Item 115) The method according to any one of items 109 to 114, further comprising diagnosing the subject having the disease based at least partially on the presence or absence of one or more genetic variants, or based on a PRS at least partially on one or more genetic variants. (Item 116) The method according to any one of items 109 to 115, further comprising treating the subject based on the presence or absence of one or more genetic variants. (Item 117) A method for determining the phase of germline mosaic variants in a subject, Obtaining a reference genetic code comprising two sets of phases, each set of phases having one or more variants of interest, and optionally, the reference genetic code having at least partially determined phases; Obtaining a plurality of sequenced reads using a non-error propagation technique, wherein each read includes at least one of one or more variants of the subject of interest; Based on the aforementioned multiple leads, the phase alignment of the two sets of phases is determined to be either the same phase or different phases; Based on the determined phase alignment of the two sets of phases, identify haplotypes containing chromosomal segments exhibiting aneuploidy (e.g., CNV); Methods that include... (Item 118) The method according to item 117, wherein the subject is diagnosed with or suspected of having a genetic disorder or condition related to the aneuploidy, and optionally, the subject is diagnosed with or suspected of having Noonan syndrome or rhasopathy. (Item 119) The method according to item 117 or 118, further comprising screening gametes from the subject for the identified haplotype. (Item 120) The method according to item 119, further comprising selecting gametes that do not have the identified haplotype for in vitro fertilization. (Item 121) The method according to any one of items 117 to 120, further comprising screening for the haplotype in the embryo during preimplantation genetic testing. (Item 122) The method according to item 121, further comprising selecting embryos based on the absence or presence of the aforementioned aneuploidy, and optionally, selecting the embryos from a plurality of embryos. (Item 123) The method according to item 122, further comprising using the selected embryo in in vitro fertilization (IVF). (Item 124) The method according to item 122, further comprising disposing of the selected embryos. (Item 125) The method according to item 122, further comprising freezing the selected embryos. (Item 126) The method according to any one of items 117 to 125, wherein the aforementioned aneuploidy is identified by performing the method according to any one of items 32 to 81. [Brief explanation of the drawing]
[0038] [Figure 1] Figure 1 shows simulated allele balance data for human chromosome 21, with amplification between approximately nucleotide positions 30.2 Mb and 44.3 Mb. [Figure 2] Figure 2 shows simulated allele balance data averaged across haplotype blocks. The arrows indicate the approximate location of the switch error in the input phase-determined genotype data that would cause monosomy, rather than trisomy, to occur downstream of the simulated switch error in the chromosome. [Figure 3] Figure 3 shows simulated allele balance data, averaged over a 300Kb window of haplotype blocks, illustrated at the bottom of the figure, across the chromosomal regions where aneuploidy is detected. [Figure 4] Figure 4 shows a summary of the Hi-C data of the genetic sample simulated from the allele balance data. [Figure 5] Figure 5 shows the true allele balance signal after the switch error has been corrected. [Figure 6]Figures 6A–6B illustrate simulated true allele balance signals for scenarios involving a mixture of chromosomes including normal bichromosome regions and abnormal trichromosome regions. Figure 6A shows the signals for individual measurements, and Figure 6B shows the signals when averaged across haplotype blocks. [Figure 7] Figure 7 schematically shows two different signals, a dichromosome measurement population and a trichromosome measurement population (shaded) as normal distributions extending across X1 and X2, where m1 and m2 refer to the mean measurements for the trichromosome population (three chromosome regions of the chromosome). [Figure 8] Figures 8A and 8B show read depth data for chromosomal regions with simulated amplification. Figure 8A shows the raw depth signal for each indexed position, and Figure 8B illustrates a histogram showing the percentage of measured values for various binned read depths. [Figure 9] Figures 9A–9C show allele balance data for chromosomal regions with simulated amplification. Figure 9A shows the raw allele balance signal for each indexed location, and Figure 9B illustrates a histogram showing the frequency of measurements for various binned proportions of the A allele. Figure 9C further shows a histogram where the measurements are averaged across 50 adjacent SNPs. [Figure 10] Figure 10 shows the depth signals of reads that are offset against the depth signals of disomy reads and normalized for the noise (standard deviation) of the depth signals of trisomy reads over simulated amplification (trisomy) between positions 30 Mb and 37 Mb. [Figure 11] Figure 11 shows the allele balance signal, which is offset against the allele balance signal of disomy and normalized for the noise (standard deviation) of the allele balance signal of trisomy, across simulated amplification (trisomy) between positions 30 Mb and 37 Mb. [Figure 12]Figure 12 shows the summation, offsetting, and normalized integration of read depth and allele balance signals. [Modes for carrying out the invention]
[0039] Detailed explanation One or more regions of the genetic code of interest (e.g., the genome of interest), particularly previously This technique clarifies the phase region that may contain switch errors, which was introduced from the error propagation phase determination technique. To achieve this, by applying nucleotide sequencing methods that are inherently non-error propagation, A method for making improved determination of numerical states is disclosed herein, via a non-error propagation method. The phase alignment determined between two or more variants of the subject of interest is the genetic dark spot of the subject of interest. It can be combined with existing phase information regarding the number. In some examples, (for example, switch e (From phase determination techniques that have introduced Rah) One or more of the objects of interest whose phase has been inaccurately determined. The determined phase alignment can be used to correct the phase state of the riant. In a few examples, the estimated phase state of one or more variants is the true phase state. To verify this, the determined phase alignment may be used. In some cases, missing To supply the dropped phase information, the determined phase alignment may be used. The phase of a portion of the genetic code of interest, determined at least partially by the seeding method. State information can be used to (re)analyze allele balance signals. Non-erroneous transmission The true allele balance signal obtained using the dispersal phase determination method is CNV It can be used to make improved determinations of polyploidy states, such as in certain embodiments. This indicates an allele balance shift relative to the reference haplotype. To determine whether the Gnar corresponds to a deletion or amplification in the genetic code of interest Improved phase state alignment may be used.
[0040] By using allele balance signals in combination with read depth signals, Furthermore, methods for determining the ploidy state are also disclosed herein. Gunal improves the signal-to-noise ratio and reduces the probability of false positive and / or false negative calls. It provides independent information that can be reduced. Its use in combination with true alleles. To provide child balance signals, alleles are determined via a non-error transfer phase determination approach. This can be particularly powerful when the balance signal is corrected.
[0041] Phase state and switch errors A switch error occurs when the variant position is not accurately determined relative to its adjacent variants. It occurs when this happens. As used herein, "variant" refers to a single nucleotide polymorphism (S This can refer to any difference between the sequences of two or more homologous chromosomes, including NPs. If so, the variant is a tenth of the larger group unless otherwise indicated by the context. This does not imply a low frequency. Phase decision accuracy is known as the "switch error rate". By counting the number of switch errors that occur, divided by the number of opportunities for switch errors, It can be measured as follows: Switch error, long switch error, point switch error. It can be classified as a switch error, or an undetermined switch error. There are no other surrounding local switches (for example, within three consecutive heterojunction sites) It appears as a large-scale pseudo-recombination event (where the switch does not exist). The point switch consists of two Adjacent switch errors (for example, two switches within three consecutive heterojunction sites) A small switch error appears as a pair of switches (counted as one point switch). - The remaining switches are considered undetermined (for example, within a small phase determination block 2 Only one part is phase-determined, and therefore, it is not possible to classify switch errors as long or point. It was not possible. ) Because the switch error propagates across a larger portion of the genome. For example, a second switch error in a shared switch may trigger a nucleo downstream of the shared switch. Since the cide is returned to its original / appropriate phase state, the phase state of the gene locus far downstream from the coswitch is (Not affected by co-switching errors.) Long switches are related to the phase state of the gene locus. This is particularly detrimental to genome analysis that relies on this. Long switch errors are especially harmful to true haptic Compared to the haplotype, the false recombination event induced in the predicted haplotype was It can occur. A significant limitation of using phase sets is the presence of long-term switch errors. Yes, these errors occurred, especially with small (e.g., less than about 1Mb) deletions or amplifications. This directly affects the detection sensitivity. In contrast to isolated phase determination error events, switch errors... This applies to all downstream loci and / or downstream loci relative to the upstream locus. This can directly affect the relationships of all upstream loci. Low polymorphism or SNV density Genomic regions containing this feature are particularly susceptible to switch errors during phase determination.
[0042] A population-based phase determination approach that relies on computationally inferring phases from statistical analysis of populations. Therefore, the switch error rate is generally higher compared to molecular phase determination approaches. However, molecular phase determination approaches can sometimes be prone to switch errors. For example... For example, many molecular phase determination approaches involve aligning short reads to the genome. Computational construction of long reads synthesized from short reads, relying on statistically obtained inferences. It can depend on the following: For example, haplotype determination based on dilution pool sequencing can depend on the number of compartments within a given area. In order to reduce the possibility that one DNA molecule has a sequence that overlaps with another DNA molecule, This depends on the low molar concentration of molecules per compartment. Such assumptions are at least several This makes it possible to obtain haplotypes, but also long-range phase determination (e.g., whole-chromosome phase determination). Switch errors can be introduced when performing ). The most likely phase alignment is To find out, several assumptions are made regarding the phase alignment of the distant variants. This allows for the introduction of switch errors.
[0043] Experimental information that directly links one variant to another enables phase alignment. The phase alignment is determined, and the phase alignment is based on inferences relating to the phase state of the variant that is further away. Therefore, to determine the proximity of two or more gene loci in an intact chromosome, these This directly depends on the mutual determination of one or more variants at the gene locus. The existing phase determination approach is generally less prone to switch errors. Therefore, Even if an error in phase determination occurs using this approach, the error is not necessarily related to other errors. It is not guaranteed that the gene will be transmitted to more distant loci (e.g., downstream loci). Therefore, Such "non-error propagation" methods are prone to switch errors in population-based phase determination. This provides an independent phase determination approach compared to approaches and molecular phase determination approaches.
[0044] Generally, approaches that are non-false propagation and approaches that are false propagation exist in this art. It is well understood in that regard. An example of a non-error propagation approach is particularly close (for example) Chromosome three-dimensional structure capture for a set of adjacent phases (e.g., Hi-C); single cell - Template chain sequencing; and (e.g., obtained by karyotype analysis or laser capture microscopy) Examples of chromosome sequencing include, but are not limited to, methods for performing sequencing. The nature of the experimental setup used (i.e., experimentally focusing on only one chromosomal homolog) (Sequencing approaches that can or can limit reads) Sequencing techniques that can be presumed to originate from chromosomal homologs are non-error-propagating approaches. It will be understood that this is the case. Generally, apps are prone to error propagation (error propagation). One approach is one based on the sequencing of parental sperm and / or polar bodies; dilution pooling. Sequence determination; collective reference panel; and capturing two sets of phases in a single read. To enable this, the phase determination is performed within a sufficiently localized region (e.g., within approximately 50kb). Sequencing of long reads when not focusing on sets (e.g., nanopore sequencing) Examples include, but are not limited to, running.
[0045] According to some aspects of the present invention, in order to provide accurate phase determination of a targeted region Non-error transfer methods may be used for targeting regions of DNA. The phase state information obtained can be combined with the phase state information obtained from the error propagation method. For example, the estimated phase state alignment (e.g., the phase state obtained from the error propagation method) To identify and correct switch errors in and / or estimated phase states To verify the alignment as true alignment, obtained from a non-error propagation method Phase state information can be used. Phase state information obtained from a non-error propagation method is used to estimate the phase In state alignment (for example, phase states obtained from error propagation methods), missing phase information It can be used to supply information.
[0046] Ploidy state The ploidy status of a chromosome or chromosomal segment can be broadly characterized as either euploidy (having a normal copy number) or aneuploidy (having an abnormal copy number). The amount of genetic material present at one or more loci may be used to determine the ploidy status of a genetic sample. Aneuploidy may include, for example, unbalanced translocations, uniparental disomy, or other global chromosomal abnormalities, including copy number variations (CNVs).
[0047] Copy count variations CNVs generally refer to variations in the number of repeats in a repeating genomic compartment between individual chromosomes. Approximately two-thirds of the entire human genome may consist of repeats, and 4.8–9.5% of the human genome may be classified as CNVs. CNVs are known to predict disease phenotypes to some extent. CNVs can affect the number of short repeats (e.g., dinucleotide or trinucleotide repeats) or long repeats (e.g., whole gene repeats) and are generally introduced by duplication or deletion events. CNVs are often assigned to one of two main categories based on the length of the affected sequence. The first category includes copy number variations (CNPs), which are common in the general population and occur at an overall frequency of over 1%. CNPs are typically small (mostly less than 10 kb in length) and are often abundant in genes encoding proteins important in drug detoxification and immunity. A subset of these CNPs is highly variable with respect to copy number. As a result, different human chromosomes can have a wide range of copy numbers (e.g., 2, 3, 4, 5, etc.) for specific sets of genes. CNPs associated with immune response genes have recently been linked to susceptibility to complex genetic disorders, including psoriasis, Crohn's disease, and glomerulonephritis.
[0048] The second class of CNVs ranges in size from several hundred thousand base pairs to over one million base pairs. This includes relatively rare variants that are much longer than CNP. In some cases, These CNVs are generated during the formation of sperm or eggs that give rise to a specific individual. These may be acquired through inheritance, or passed down within a family for only two or three generations. Structural variants are biased towards individuals with intellectual disability, developmental delay, schizophrenia, and autism. They have been observed. Their appearance in such objects is large and rare CNVs, single More important in neurocognitive disorders than other forms of hereditary mutations, including nucleotide substitutions. This led to the speculation that it was possible.
[0049] Gene copy number can change in cancer cells. For example, Chr1p duplication can occur in breast cancer. It is common for EGFR copy numbers to be higher than normal in non-small cell lung cancer. Cancer is one of the leading causes of death, and therefore (increases the probability and duration of remission) Because it can improve patient outcomes (through these means), early diagnosis and treatment of cancer It is important. Early diagnosis allows patients to receive less or less intense treatment options. This can also be made possible. Many of the current treatments that destroy cancerous cells also have an effect on normal cells. Symptoms include nausea, vomiting, low blood cell count, increased risk of infection, hair loss, and ulcers in the mucous membranes. This can lead to various possible side effects. Therefore, early detection of cancer is important for eliminating cancer. Reduce the amount and / or number of treatments required (such as chemotherapy or radiation). This is desirable because it allows for this.
[0050] Copy number variations are associated with severe mental and physical disabilities, as well as idiopathic learning disabilities. Non-invasive prenatal testing (NIPT) using extracellular DNA (cfDNA) can be used to detect abnormalities such as fetal trisomy 13, 18, and 21, triploidy, and sex chromosome aneuploidy. Subchromosomal microdeletions, which can also result in severe mental and physical disabilities, are more difficult to detect due to their smaller size. Eight microdeletion syndromes have an overall incidence of over 1 in 1000, making them almost as common as fetal autosomal trisomy. Furthermore, higher copy numbers of CCL3L1 are associated with lower susceptibility to HIV infection, and lower copy numbers of FCGR3B (CD16 cell surface immunoglobulin receptor) may increase susceptibility to systemic lupus erythematosus and similar inflammatory autoimmune disorders.
[0051] Determination of ploidy status Various aspects of the present invention relate to either chromosomes or chromosomal segments, and to specific subjects and details. Determination of the ploidy status of a cell or a group of cells, or other sources of genetic material. This includes making a call (for example, calling a CNV). When used herein, A chromosomal segment can be characterized as having a copy number and containing the entire chromosome. This can refer to any length or portion of the sequence of chromosomes. The subject is a genome, preferably a diploid genome. It can refer to any organism that possesses a 'mu'. Preferably, the subject may be a mammal. Various situations According to this, the subject is humans. Determining the ploidy state is equivalent to determining the origin of aneuploidy (that is, This may include determining which chromosomal homologs contain aneuploidy. The origin is, for example, If so, it can be identified as originating from a chromosome inherited from the mother or father. .
[0052] The ploidy status of a chromosome or chromosomal segment can be determined with respect to the reference genetic code. The reference genetic code is the entire genome of the subject, the entirety of one or more chromosomes of the subject, or the subject This can correspond to one or more chromosomal segments (on the same or different chromosomes). The reference genetic code is the subject of analysis of the genetic material according to the methods disclosed herein. It can be obtained directly or indirectly. For example, the reference genetic code is obtained from normal inheritance from the subject. It can originate from the sequencing of material (e.g., normal cells or non-cancerous cells). Normal genetic material is , either it is known to be a field of superploids, or the aneuploidy of known properties has been previously identified It may be the genetic material present. The reference genetic code is found in the somatic cells and / or germline cells of the subject. It can be obtained from sequencing. In some cases, the reference genetic code is obtained, especially if the subject is an embryo or fetus. If it is a child, one of the subjects whose genetic material is being analyzed according to a method known in the art is This is obtained by reconstructing the genetic code from the sequencing of multiple parents or other genetically close relatives. It may be obtained. For example, the entirety of which is incorporated herein by reference, April 2021 Please refer to International Publication No. 2021 / 067417 by Kumar et al., published on the 8th. Constructing a reference genetic code involves the somatic cell tissue of one or more genetically related individuals and / or This may include sampling germline tissue. Constructing a reference genetic code is Even if only a small amount of genetic information can be obtained, the subject (e.g., embryo or fetus) can be sampled. This may include ringing. Constructing a reference genetic code involves cells obtained from a subject. This may include sequencing. Constructing a reference genetic code can be done in the blood or cell culture of the target organism. DNA fragments from the culture medium (in the case of an embryo) or from the blood of the mother (in the case of a fetus) are sampled. This may include sequencing extracellular DNA (cfDNA) through processes such as sequencing. In some embodiments, the genome of the target, or at least the genome of the target normal cell. M is used to determine the ploidy state of abnormal cells (for example, tumor cells, etc.) It functions as a reference genetic code that can be compared. In some embodiments, The expected genome of the elephant (i.e., de novo polyploid states such as de novo amplification or deletion events) A genome (composed of specific chromosomes inherited from the parent of the subject, in which no changes occur) To determine the de novo change to a ploidy state in the subject, a comparison is made with it. It serves as a reference genetic code that enables this.
[0053] The reference genetic code does not need to have a determined phase. Preferably, the reference genetic code is completely The phase is determined, or at least partially determined. The reference genetic code is The phase is determined by any method known in the art, such as an error propagation phase determination approach. It can be determined. For example, the genetic code can have its phases determined by computational techniques that include a reference population panel. The genetic code can be determined by molecular techniques such as dilution pool sequencing. For example, Choi et al., PLoS Genet. 2018 Apr 5;14( 4):e1007308(doi:10.1371 / journal.pgen.100 See 7308). The genetic code is also found in the germline cells of the subject and / or one of the subjects. Alternatively, by sequencing multiple genetically related individuals (e.g., mother and father), the phase can be determined. It may be determined. For example, the entirety of which is incorporated herein by reference, April 2021. Please refer to International Publication No. 2021 / 067417 by Kumar et al., published on the 8th of the month. .
[0054] A haplotype is a continuum of genomic variants specific to any one of the chromosomal homologs. This is the block that was determined. Depending on the circumstances, the method of the present invention described herein Before proceeding, ensure the certainty of correct phase determination within the haplotype block, or at least ten percent. Haplotype blocks can be pre-constructed to ensure high reliability. The haplotype block is defined as a block in which no switch errors exist. From dilution pool sequencing or long-read sequencing where certainty or high reliability exists It can be constructed. Obtaining prior phase state information for the genetic code of interest is one step. This may include obtaining multiple haplotype blocks. In various embodiments, the present invention One or more of the signals described in the document may occur across haplotype blocks, This can be averaged over smaller regions or sections of the haplotype block.
[0055] Non-error propagation phase determination approach In various embodiments, the non-error-propagating phase determination approach is compared to the error-propagating phase determination approach. Combining them can be advantageous. Non-error-propagating phase determination techniques are more traditional than error-propagating techniques. It can provide an independent source of information for the technique. Error propagation phase determination approach (e.g.) , population-based phase determination and molecular phase determination approaches described elsewhere in this specification (C) is a non-fault-propagating approach for obtaining large-scale array and / or phase state information. It may offer a faster, cheaper, and / or more convenient approach than [unclear]. The seeding approach allows for better determination of the ploidy state (for example, its target (Improves the ability to call CNVs within a region) Regarding the targeted region of the genetic code It can provide more accurate phase state information.
[0056] Phase alignments that can be obtained from non-error propagation techniques can be used in a targeted manner. Depending on the method used, targeted phase correction focuses on a specific region of the genetic code. It can be combined, saving resources and making one or more non-false propagation methods or more efficient. Enables rapid implementation. For example, identified from genomes that have been at least partially phase-determined. The phase states of a specific set of phases related to a potential switch error are their true set It can be used to correct the phase state. Phase alignment involves staining the genome and the object of interest. can be used to re-analyze the entire phased alignment of a body or a chromosomal segment of interest The phased state can be used to provide missing phase information for a particular variant or chromosomal segment The phased alignment can be computationally recalculated using the phased alignment in combination with prior phased state data (e.g., obtained from an error propagation approach) The methods of combining phased state alignments obtained from the methods described herein with existing phase information are well understood in the art According to one aspect of the present invention, error-free propagation techniques can be used in combination with conventional error propagation techniques to provide an improved process for reconstructing the entire genome based on the obtained more accurate phased state information Error-free propagation techniques may also enable interpretation of the function of variants in the genome As described herein, various phasing approaches that are understood to be error-free propagation are well known in the art Specific but non-limiting examples of such techniques that can be used in an error-free propagation manner are described herein
[0057] Chromosome conformation capture (3C) Chromosome conformation capture (3C) technology is a molecular biological method used to analyze the spatial organization of chromatin in cells The 3C method generally detects interactions between genomic loci that are close in three-dimensional space, including loci that may be separated by many nucleotides in the linear genome sequence (e.g., loci that may be too far apart to be captured together by short read and / or long read sequencing)
[0058] Chromosome conformation capture (3C) Chromosome conformation capture (3C) technology is a molecular biological method used to analyze the spatial organization of chromatin in cells The 3C method generally detects interactions between genomic loci that are close in three-dimensional space, including loci that may be separated by many nucleotides in the linear genome sequence (e.g., loci that may be too far apart to be captured together by short read and / or long read sequencing) Interactions between genomic loci that are close in three-dimensional space, including such loci The number of such interactions is quantified. Examples of such interactions include promoter-enhancer interactions. These can be due to biological functions, or to the non-directional physical movement of chromatin causing collisions at gene loci. This can result from random polymer looping. Can the interaction frequency be directly analyzed? Alternatively, the interaction frequency can be converted into distance, which facilitates the reconstruction of the three-dimensional structure. Obtain. Different 3C-based methods exhibit different ranges regarding genome-wide interactions that can be investigated. It may have a bounding box. To create a genome-wide interaction map, it is constructed using 3C. Deep sequencing of the material may be used.
[0059] The 3C method involves the digestion of DNA in cross-linked chromatin within the cell nucleus and subsequent regeneration. Egation enables the detection of spatial proximity between DNA sequences. One 3C technology is high This is based on throughput sequencing technology. In standard 3C-based protocols, Chromatin is usually cross-linked with formaldehyde. Then, the cross-linked chromatin Typically, the genome is cut into segments approximately every 256 bp or 4096 bp. It is fragmented by restriction enzymes. Then, in situligation is performed on the contacting chromatin. Ensure preferential ligation between chromatin fragments and cross-linked chromatin fragments. Machin is digested so that the bridges are reversed, and the sha are linked together according to spatial proximity. Linear and / or circular DNA concatemers carrying ffled genome fragments are produced. It will be done.
[0060] 3C technology includes classical 3C, 4C, 5C, Hi-C, and ChIA-PET methods. The classic 3Cs, often called the "one-to-one" approach, are specifically targeted and PCR is used to amplify and quantify the ligation junction. "1 to 1" app 4C, often called roach, undergoes a second digestion to produce a small DNA ring. It is similar to classical 3C technology, except that ligation is performed. Next, To amplify all contact sequences that formed the ligation product with the ker sequence, Primers designed for anchor sequences can be used in reverse PCR, The latest method can avoid the need for amplification. Then, the contact array is connected by any suitable means. The sequence can be determined by this. 5C, often called the "many-to-many" approach, exists In order to create a copy of the joint of the object of interest to the extent that, complementary plastics are used for the fragment of the object of interest. The imer is hybridized to a 3C ligation product and then linked. Then, optionally To amplify the ligation product of interest which can be sequenced by appropriate means , universal PCR primers (primaries) complementary to the tail of the original primer ) is used. Hi-C, often called the "whole-to-whole" approach, uses biotin labeling. Use restriction enzymes that leave overhangs filled with nucleotides. After igation, the ligation product is sheared to reduce the fragment size, and streptoavi A concentrated library was prepared by removing biotin-containing fragments using gin, and then Typically, this is sequenced using NGS technology. Hi-C is fragmented throughout the genome. This gives a matrix of pair interaction frequencies between them. Resolution is achieved by using a higher restriction site density. This can be improved by increasing the sequencing depth, x 2Sequencing of a large number of pairs generally provides an x-fold improvement in resolution. Particularly in Hi-C, the measured values corresponding to individual variants of interest may be sparse, but since the measured values across the entire chromosome are generally consistent, they can be used as a whole to improve phasing determination across the entire chromosome . ChIA-PET is a combination of Hi-C and chromatin immunoprecipitation (ChIP). Prior to biotinylating and ligating the fragment ends, specific antibodies are used to remove ligation junctions bound by the chromatin protein of interest . Other chromosome conformation capture techniques known in the art include Tethered Conformation Capture (TCC), DNase Hi-C or Micro-C, Targeted Chromatin Capture (T2C), Capture Hi-C (Chi-C), HiCap and Capture-C. Various methods for performing chromosome conformation capture are described, for example, in Denker, et al., Genes Dev. 2016 Jun 15;30(12):1357-82 (doi:10.1101 / gad.281964.116); de Wit, et al., Genes Dev. 2012 Jan 1;26(1):11-24 (doi:10.1101 / gad.179804.111); McCord et al., M ol Cell. 2020 February 20;77(4):688-708) (doi:10.1016 / j.molcel.2019.12.021); or Bel ton et al., Methods. 2012 Nov;58(3):268-76 (doi:10.1016 / j.ymeth.2012.05.001), each of which is incorporated herein in its entirety by reference .
[0061] To determine the genome phase using non-error transfer methods, chromosome three-dimensional structure capture techniques are used. This is possible. Based on their unique spatial proximity, the gene locus on the same chromosomal homolog can The probability of them being linked together is far greater than the probability of two homologous chromosome loci being linked together. Because it is high, the overall distribution of ligation fragments generated by 3C technology is two or more Compared to variants from different homologs above, variants from the same chromosomal homolog It can be assumed that it has an advantage. Furthermore, its effect is that the variant or set of phases The closer they are to each other, the more dominant they become. Therefore, without the concern of introducing a switch error, two To align phases, especially sets of two adjacent phases, chromosome three-dimensional structures such as Hi-C are used. Capture techniques can be used.
[0062] The distribution determines whether two sets of phases are the same or different. To determine this, the distribution of fragments (ligation products) obtained from the chromosome three-dimensional structure capture method was determined. This can be analyzed. A fragment containing at least one variant is selected from each set of phases. Therefore, fragments can be filtered. Fragments that support the same haplotype call They can be grouped into subgroups corresponding to different sets of variants, but each fragment is They do not have to include the same variant. In some embodiments, the fragments are one or Only fragments containing each variant from both sets of phases can be filtered. Each set of phases has a presumed phase or haptic alignment, just as there is a presumed phase alignment. A type may be assigned. If no prior phase determination has been made, the phase alignment will be It can be assigned randomly. The selected fragments and / or subgroups are estimated phases. They can be characterized as matching or mismatching with respect to alignment. For example, within a fragment, If all the variants produced originate from the same presumptive haplotype, then the fragment is a presumptive variant. The fragment may be considered to match the linement, otherwise it may be considered to be a mismatch. In the case of a variant that is adjacent to another variant, variants derived from the same haplotype or chromosomal homolog. Given that the probability of a fragment containing is significantly higher, the distribution of fragments / subgroups is consistent. Alternatively, it can be expected that there is a significant bias towards the direction in which mismatched fragments are dominant. Matching fragments The dominance of the subgroup suggests that the presumptive phase alignment is correct. In contrast, the predominance of inconsistent fragments indicates that the presumptive phase alignment is incorrect. This suggests that the amount of bias can be quantified by calculating the probability of observing the bias by chance. This can be done. For example, the binomial probability can be calculated for the probability of observing the measured distribution by chance. Each measurement has a certain probability of agreeing or disagreeing. The certain probability is 50% of the phases. As a lower bound, suggesting that the ligation of the set is completely random, It can be determined. Alternatively, in order to consider a higher probability expected from spatial proximity, The probability that a set of phases from the same haplotype exists within the same fragment is set to a higher value. Obtain (for example, 60%, 70%, 75%, 80%, 90%, 95%, 99%, 99.9%) (etc.) A higher constant probability may be more useful for a smaller number of measurements. Therefore, a lower constant probability may be sufficient for a larger number of measurements. The fabric is not simply a result of chance (for example, the measurements are statistically significant with respect to a 95% confidence interval) If there is a high level of confidence that (this is true), the phase set is based on chromosome three-dimensional structure data. It can be precisely aligned.
[0063] Single-cell template chain sequencing Single-cell template strand sequencing (Strand-seq) uses sequence analysis during DNA replication. Single cell isolation of individual homologs within a cell by restricting to the DNA template strand being used. This is a sequencing technique. This method involves labeling the newly generated DNA strand and then selectively removing it from the analysis. To enable this, cells are cultured in a thymidine analog during a single cell division. This depends on the orientation of the DNA (distinguished by the 5'-3' orientation of the DNA). (to be done). Each single-cell library is multiplexed for storage and sequencing, and the obtained sequence The data is aligned and mapped to either the minus or plus strand of the reference genome. Assigns the template strand state of each chromosome within the cell. For example, each of them as a whole is referenced. More specifically incorporated herein, Porubsky et al., Genome Re s.2016 Nov;26(11):1565-1574(doi:10.1101 / gr.209841.116);Sanders et al., Nat Protoc .2017 Jun;12(6):1151-1176(doi:10.1038 / np See rot.2017.029). Sequencing may be limited to single strands, so The technology may be used as a non-error propagation method as described herein.
[0064] Chromosome isolation Since all sequence reads can be presumed to originate from the same homolog, before sequencing, Any technique for physically isolating one chromosome homolog from another chromosome homolog is relevant to phase determination. This can be considered a non-error propagation approach. For example, in karyotype or laser capture microscopy. The resulting chromosome sequencing can be used for the non-error propagation techniques described herein. It may be used. For example, Kang et al., whose entire work is incorporated herein by reference. al.,Cytogenet Genome Res.2017;152(4):204 See -212 (doi:10.1159 / 000481790).
[0065] Sequence determination method Various methods for DNA sequencing are well known in this art and are not specifically indicated by the context. Insofar as it is used, the methods described herein may be used to carry out the DNA sequencing. For example, this may include Sanger sequencing (chain stop sequence determination). DNA sequencing is the next generation sequence This may include the use of next-generation sequencing (NGS) or second-generation sequencing techniques, which are typically highly advanced. It is characterized by its scalability and the ability to sequence the entire genome at once. GS technology generally allows for the sequencing of multiple fragments at once, enabling automated processing. This enables "ultra-parallel" sequencing in the process. DNA sequencing is third-generation sequencing. This may include techniques (e.g., nanopore sequencing or SMRT sequencing), which generally refers to the first This makes it possible to obtain longer reads than can be obtained through two-generation sequencing techniques. If feasible, sequencing involves sequencing both ends of a DNA fragment using paired-end sequencing. This may include decisions that could improve the ability to align reads to longer sequence decisions. DNA sequencing is performed using synthesis / ligation (e.g., ILLUMIN). A(registered trademark) sequencing), single-molecule real-time (SMRT) sequencing (e.g., PAC BIO(registered trademark) sequencing), nanopore sequencing (e.g., OXFORD NANOP) ORE (registered trademark) sequence determination, Ion semiconductor sequence determination (Ion Torrent sequence determination) This includes (determination), combinatorial probe anchor synthesis sequence determination, pyrosequencing, etc. It is visible.
[0066] Shotgun sequencing uses random DNA strands from a genome or large genetic sample. This refers to a method of sequencing. DNA is randomly divided into many small segments, and these The data is then sequenced (e.g., using the chain termination method) to obtain reads. This fragmentation and sequencing process... By performing this process several times, multiple duplicate reads for the target DNA are obtained. The calculation algorithm assembles random segment reads into a contiguous array. This uses overlapping ends of different reads. Shotgun sequencing is a method of whole-genome sequencing. It may be used for determination. As described elsewhere in this specification, its variants The basis for measuring the genetic signals that indicate ploidy status in the chromosomal segments and To identify variants (e.g., SNPs) in the subject that can be used thereafter, Any suitable form of sequencing determination, including those described herein, may be used. In certain aspects, hierarchical sequencing can be used for whole-genome sequencing.
[0067] Data collection The genetic material for analysis by the methods described herein is somatic cells (e.g., leukocytes, Includes cells from tissue biopsy, germ cells (e.g., sperm, eggs, polar bodies), and extracellular DNA. Genetic material can be obtained from various sources. Genetic material is obtained from the subject whose genome is being analyzed and / or Alternatively, it may be collected directly from the subject's genetic relatives (e.g., mother and / or father). According to various embodiments, allele balance signals or read depth signals, etc. The genetic signal indicating ploidy is either derived directly from extracellular DNA (cfDNA) of the subject or Extracellular DNA can be obtained from sources such as bloodstream or outside the body. Freely circulating in the cell culture medium of cultured cells such as embryos grown for fertilization (IVF). It is DNA.
[0068] Various embodiments of the methods described herein include obtaining extracellular DNA and / Or it may include sequencing. Extracellular DNA is extracellular fetal DNA (cffDNA). Extracellular DNA may include circulating tumor DNA (ctDNA). A is a non-invasive or low-risk method, such as sampling cell culture media or taking blood from a subject. Cells can provide a relatively abundant source of genetic material that can be obtained from invasive procedures. Extracellular DNA contains sufficient genetic information for whole-genome sequencing of the target from which the extracellular DNA originates. It can be provided. For example, Kitzman et al., Sci Transl Med. 2012 Jun 6;4(137):137ra76(doi:10.1126 / sc See itranslmed.3004323). For example, one or more of the targets. Shotgun sequencing of extracellular DNA can be used to sequence a number of chromosomes. The genetic material from the subject may have cells with a consistent genetic profile, or different ones. It may have cells with different genetic profiles (e.g., normal cells and tumor cells). In that example, the target genome was sequenced and 1 / 2 of the genetic material obtained directly from the target. It can be reconstructed based on the sequencing of multiple genetic relatives. For example, the whole thing can be referenced More relevant to this specification is the international publication by Kumar et al., published on April 8, 2021. Please refer to publication No. 2021 / 067417.
[0069] Extracellular fetal DNA (cffDNA) is fetal DNA that circulates freely in the mother's bloodstream. Therefore, cffDNA can be obtained, for example, from maternal blood collected by venipuncture. CffDNA analysis can be recommended to pregnant women as a non-invasive prenatal diagnostic method. This is the law. cffDNA originates from the trophoblast cells of the placenta. Tiny particles of the placenta are transferred to the mother's blood. When released into circulation, fetal DNA is fragmented into cffDNA, which is approximately 200 bp long. The fragments are significantly smaller than the maternal DNA fragments, making them distinguishable from the maternal DNA fragments. Yes, it is possible. Approximately 11-13.4% of the extracellular DNA in the mother's blood is cffDNA, but The amount varies greatly among pregnant women. CffDNA is generally detectable after 5-7 weeks of gestation. The amount of cffDNA in the mother's blood increases as pregnancy progresses. cffDNA decreases rapidly after childbirth and is generally no longer detectable about two hours after delivery. The analysis may provide earlier diagnosis of the fetal condition than other techniques. cffDNA, for example, , massively parallel shotgun sequencing (MPSS), targeted massively parallel sequencing (t-MPS) and It can be analyzed by SNP assay.
[0070] ctDNA is fragmented DNA from tumors in the bloodstream that is not attached to cells. Because ctDNA can reflect the entire tumor genome, its potential clinical utility is gaining momentum. The "liquid biopsy" method, a form of blood sampling, is used to monitor tumor progression throughout the treatment regimen. It can be collected at various points in time. ctDNA is found in the tumor or shed from the primary tumor and into the bloodstream. Circulating tumor cells (CTCs), which are living, intact tumor cells that enter the bloodstream or lymphatic system, are directly affected by The exact mechanism of ctDNA release remains unknown. The hypothesized biological processes include apoptosis and necrosis from dead cells, or living cells This includes active release from tumor cells. (Human (healthy and cancer patients) and xenografted mice) Studies in both areas have shown that the size of the fragmented cfDNA is mainly 166 bp long, This indicates that it corresponds to the length of the DNA wrapped around the nucleosome + linker. This length of fragmentation may indicate apoptotic DNA fragmentation, and apotosis This suggests that this could be the primary method of ctDNA release. Fragmentation of cfDNA is , it changes in the plasma of cancer patients. In healthy tissue, invasive phagocytic cells have an apothecaryocyte containing cfDNA. It is responsible for removing ptosis or necrotic cell debris. cfDNA is present at low levels in healthy patients. Although it is merely present, higher levels of ctDN are observed in cancer patients as tumor size increases. A can be detected. This likely reduces the effective elimination of ctDNA from the bloodstream. This is caused by inefficient immune cell infiltration into the tumor site, resulting in ctDNA and the same By comparing mutations in DNA extracted from the primary tumors of the same patient, identical cancer-related gene changes were identified. The existence of ctDNA has been revealed, making it possible to analyze ctDNA in order to analyze the genetic structure of tumor cells. The possibility was tolerated. Therefore, ctDNA is used for earlier cancer detection and treatment follow-up monitoring. It can be used for taring.
[0071] According to various aspects of the present invention, the non-error propagation phase determination techniques described elsewhere in this specification To provide accurate phase determination (for example, to compensate for any switch errors), Tactile chromosomes are isolated or effectively isolated, so as to cellular DNA (extracellular D This is performed on (not NA). In some embodiments, as described herein. Single-cell sequencing may be performed on one or more cells to obtain data. Genetic data obtained using non-error transfer phase determination techniques can independently analyze the target genome. It may be sufficient to construct or to independently provide a sufficient reference genome. Or it may not be sufficient. Conventional sequencing techniques combined with error propagation phase determination approaches. Obtained from techniques (e.g., whole-genome shotgun sequencing of extracellular DNA, etc.) Genetic data can be advantageous in providing depth and / or scope of genetic information. Genetic data obtained from non-error transfer phase determination approaches (which can be performed on cellular DNA) This method offers more accurate phase determination for various sets of phases, especially sets of adjacent or neighboring phases. It may be advantageous to provide this information. Therefore, using these independent sources together is beneficial. This could be advantageous.
[0072] According to some aspects of the present invention, sequencing of cellular DNA is performed on blood cells (e.g., leukemia). Spheres) or other cells collected through non-invasive or minimally invasive techniques (e.g., in saliva) This can be performed on cells found in the cell. Therefore, it is exclusively for extracellular DNA and cellular DNA. Sequence determination of A can be performed by non-invasive or minimally invasive procedures such as blood sampling. Extracellular D NA and cellular DNA can be obtained from the same or different samples (e.g., blood sample or saliva sample). It can be isolated from any bodily fluid sample. For example, extracellular DNA may contain ctDNA, and cell D NA contains white blood cell DNA (which should provide normal genetic material, except in the case of leukemia). It is visible.
[0073] According to some aspects of the present invention, sequencing of cellular DNA is well understood in the art. This may include isolating one or more cells from a fetus or embryo according to established methods. Such approaches typically involve invasive techniques that could pose a risk to the embryo or fetus. It is required. According to a preferred aspect of the present invention, it is used for a non-error propagation phase determination approach. The cellular DNA to be extracted is obtained using non-invasive or minimally invasive techniques such as blood collection or sperm collection. Non-invasive or minimally invasive techniques for sequencing cellular DNA can be obtained from embryos as well. In the case of a fetus, this may be impossible for the cells of the subject itself, but the sequencing of cellular DNA is possible. The determination may be made for the fetus's genetic relatives (e.g., mother and / or father). Error propagation phase determination can only be used to provide the exact phase state of a set of phases, and not necessarily Also, independently construct the genetic code and / or generate signals indicating ploidy status. Since it is not used for that purpose, the true phase state of the target genome is a small number of the same haplotypes as the target. It can be estimated from the true phase state of the genomes of one or more genetically close relatives who have inherited at least some of the traits. This may be the case. Therefore, the methods described herein include cases where the subject is an embryo or fetus. This is performed on genetic material obtained by completely non-invasive or minimally invasive methods. obtain.
[0074] Genetic signals indicating ploidy status As used herein, “signal” refers to the genetic composition of the genetic sample being investigated. It may refer to one or more measurements that can provide information. The measurements are raw measurements. The processed values obtained, or derived from the mathematical analysis of, for example, one or more raw measurements. It may be a measured value. The signal may be obtained from sequencing data. The signal is as specified herein. As described elsewhere, for example, allele balance signals or reads It may be a depth signal. The signal is a value along a continuous or discrete spectrum. It can respond to this. The signal can indicate genetic information at a specific gene locus. The signal can be averaged from signals measured across multiple gene loci.
[0075] A gene locus is a specific, fixed location on a chromosome. A gene locus is a location for a specific gene. Identify the chromosomal location of the genetic marker. When used herein, the gene of interest A locus is one or more measurements used to derive a signal indicating the genetic composition of the genetic material. This can refer to a gene locus within the analyzed genetic material that can be mapped to that gene locus. A variant of interest is found at the locus of interest between two or more chromosomal homologs within the genetic material. SNPs can refer to the locus of interest in which differences in gene composition exist. It may be a variant of the specified term. As used herein, “set of phases” is defined as described herein. One of the objects of interest whose phase alignment with another set of phases can be determined according to the method described. It can refer to a set of one or more adjacent variants. In some examples, it can refer to a set of phases. This refers to a chromosomal region larger than a haplotype block or a haplotype block (for example, It can correspond to a block of two or more adjacent haplotypes. For example, a set of phases may be 2 5, 10, 50, 100, 500, 1,000, 5,000, or more It may include riants. In some examples, a set of phases may consist of a single variant. Two aligned sets of phases may have the same number of variants of interest. or may not have. Determine the phase alignment of one set of phases with another set of phases. To determine that two sets of phases are the same phase (i.e., the objects of interest within each set of phases) Variants of a chromosome belong to the same chromosomal homolog, or the two sets of phases are different. It is a phase (that is, a variant of the object of interest in the set of the first phase is in the set of the second phase) This includes determining that the variant of interest does not belong to the same chromosomal homolog as the variant within it. It is possible.
[0076] In some specific situations, a set of phases can be a set of adjacent phases. For example... Then, the first set of phases is derived from approximately 1,000 variants of interest in the adjacent set of phases. 0, approximately 5,000, approximately 10,000, approximately 50,000, approximately 100,000, approximately 5,000,000, approximately 1,000,000, approximately 5,000,000 Base pairs of interest not farther than approximately 10 million, 50 million, 100 million, or 250 million base pairs It may have elephant variants. The set of adjacent phases may be any of the potential switch errors. It can be defined to include the variant of the object of interest on the side. Potential switch errors are It can be identified as something that can occur between two haplotype blocks. According to this perspective, one or more signals move from the euploid segment to the aneuploid segment. Regions suggesting a shift between chromosomal segments, either to or from the opposite direction, indicate potential swirls. It can be identified as a strike error. According to some specific circumstances, one or more strike errors may occur. Null indicates a region that suggests a change in copy number relative to adjacent segments, potentially indicating a shift. It can be identified as an error. Depending on certain circumstances, one or more signals staining of different aneuploid states (e.g., from trisomy to monosomy, or vice versa) Areas suggesting shifts between chromophore segments can be identified as potential switch errors. ru.
[0077] Allele balance (balance of alleles, allele frequency, or allele frequency) (Synonymous with) is sequencing data that covers the positions of variants supporting that variant. This refers to the proportion of reads from a set. For example, 100 reads represent the percentage of a particular variant. It is mapped to the constellation Dendrobium, of which 25 support that variant and 75 support that variant. If the ariant is not supported, the variant will have an allele balance of 0.25. It is likely. Heterozygous loci are the most important to include in the allele balance data in the reads. A filter can be applied to a small depth. The phase of one variant relative to another variant. The pair ratio indicates the difference in the copy number of a gene locus between different chromosomal homologs in a genetic sample. To obtain, compare the number of copies expected based on the reference genetic code with the number of copies detected, for example. For example, if an amplification or deletion event occurs (e.g., all or less of the cells from which the genetic sample originated) (In some cases) it may indicate whether it occurred in one of the chromosomal homologs. Allele balance signals measured across riants are haplotype or stained. Based on the assignment of alleles to somatic homologs, haplotypes or chromosomal balance It can provide a signal for this. This allows the allele balance to act as a barrier. This becomes dependent on the phase state of the nucleotide (i.e., relatively high or low allele levels). Whether the proportion supports a high or low proportion of chromosomal homologs depends on the phase state. (The allele balance signal is altered by errors in phase determination, such as switch errors.) This is possible. Therefore, a true allele balance signal corrects phase alignment. As can be seen from this, phase correction can directly translate into allele balance correction. When used in detailed documents, the phase alignment or allele balance signal is "corrected". "To do so" means to perform a phase determination, regardless of whether the incorrect phase was actually identified and changed. To compare with previous or other presumed phase determinations, or as otherwise indicated by the context ( For example, without the phrase "correct errors," it would refer to supplying missing phase information. It can be used for this purpose.
[0078] Read depth refers to the mapping of one or more gene loci to a given locus during the sequence execution process. This refers to the number of sequence determination reads. The depth signal (or depth signal) of a read is... The total number of reads can be normalized. The read depth is determined by the sequencing machine. The absolute number of reads mapped to a locus or the reads mapped to that locus It can be expressed in various different ways, including but not limited to percentages or proportions. Therefore, for example, ILLUMIN generates sequences of 1 million clones. In highly parallel DNA sequencing systems such as HISEQ®, one gene 3,000 sequencing iterations of a locus result in a read depth of 3,000 reads at that locus. The proportion of reads at that gene locus is calculated by dividing 3,000 by the total number of reads (1 million). This represents 0.3% of all reads. Generally, the depth of reads at a given gene locus is The larger the locus, the more the allele balance signal at that locus is in the original genetic sample. The gene locus tends to approach the true allele balance. To include it, a filter can be applied based on the minimum read depth. A specific Varian The read depth of the lead, especially when normalized against the total number of reads, is comparable to other variants. This can show the relative number of copies of the variant being compared. Relative number of copies relative to the variant. For example, one or more benchmarks for the known number of copies from the reference genetic code. Comparing with the original means, for example, (for example, all or less of the cells from which the genetic sample originated). (In some cases) whether an amplification or deletion event occurred in one of the chromosomal homologs. This could indicate that.
[0079] For example, in addition to arbitrary copy number anomalies, there are also probabilistic events due to sampling, GC bias, and / or through numerous mechanisms including the heterogeneous distribution of variants across the genome Noise may be introduced into the signal. The signals described herein are generally multiple It can be averaged across adjacent loci. For example, multiple adjacent loci can be averaged across 2 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 100, 500, 1,00 It may contain 0, 5,000, or more loci. The selection of loci is based on the area of interest. It can depend on the region and their density. For example, multiple adjacent gene loci are at least Approximately 50,000, at least approximately 100,000, at least approximately 200,000, at least approximately 300,000, at least approximately 400,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least It may include all gene loci within a region of approximately 50 million or at least approximately 100 million base pairs. The number of adjacent gene loci is approximately 50,000 or less, approximately 100,000 or less, approximately 200,000 or less, approximately 300,000 or less, approximately 400,000 or less, approximately 500,000 or less, approximately 750,000 or less, approximately 1,000,000 or less, approximately 50,000,000 or less It may include all gene loci within a region of 100 million base pairs or less. The range of adjacent gene loci is: Gene loci can be selected so that they are presumed to be located on the same chromosome. Therefore, selection If aneuploidy does not exist with respect to only some of the loci within the gene, then each of the loci The true signals for allele balance or read depth should be the same. Therefore, averaging across adjacent loci is the signal described herein. It can reduce internal noise.
[0080] Combining allele balance and read depth According to various aspects of the present invention, in order to determine the ploidy state, allele balance sigma Null and read depth signals can be used in combination. Allele balance and read Each depth of the code determines the ploidy state individually, as described elsewhere in this specification. This can be shown separately. However, the noise from these signals, i.e., the part being investigated Allele balance related to the variation in the number of sequences that overlap at a specific position within a particular DNA molecule. Noise in the sequence and overlapping sequences of the DNA molecules being investigated. Since the noise in the read depth related to the fluctuations is at least somewhat independent, These signals can provide independent sources of information, and the signal-to-noise ratio is This improves the process and allows for more accurate determination of the ploidy state. This combination is the Lie of the intermediate number. (That is, determining the allele balance at a certain gene locus in sufficient detail) It's a perfectly capable lead, but with so many leads, the lead depth signal becomes clear. This may be particularly useful in scenarios where (there is no) allele balance signal. The true allele balance signal is obtained in accordance with the methods described elsewhere in this specification. To provide this, it can be corrected via a non-error-propagating phase determination approach.
[0081] Signals are used in combination according to various modes, as understood in the art. It can be used in multivariate logistic regression, log-linear modeling, and more. Neural network analysis, n-of-m analysis (at least one of a total of "m" criteria) Angleploidy is demonstrated when n criteria are met, decision tree analysis, random forest Analysis, rule sets, Bayesian methods, neural network methods, multiplication, addition, etc. They can be used in combination. There are several ways to use signals together. This may include integrating two signals into a single composite signal through mathematical operations. The signals can be multiplied or added together. In various embodiments, One or both of the signals can be multiplied by a scalar. For example, a signal can be multiplied by (for example , across multiple chromosomal locations where the signal is measured, and / or multiple runs of analysis (over) one of the noises, such as the standard deviation or variance measured in the signal This can be normalized across multiple scales.
[0082] For each signal and / or combination of signals, the gene locus or chromosomal segment To distinguish between different copy numbers of the signal, one or more threshold levels of the signal or The value can be selected as a cutoff. For example, trisomy (three copies of a gene locus). The gene locus pair within the disomy (two copies of the gene locus) A threshold may be selected to distinguish between monosomy (one copy of a gene locus) and / or monosomy (one copy of a gene locus). -) A threshold is selected to distinguish between loci present in disomy and loci present in disomy. It can be selected. The signal is a signal for different copy numbers, such as the copy number of the field of positive polyploids. For example, it may be offset against the mean signal value or otherwise normalized. The signal is such that a level of 0 indicates a polyploidy state, and a sufficient deviation from there indicates an aneuploidy state. It can be configured to show polyploidy. Different thresholds are selected to show different copy numbers. It is possible.
[0083] The use of individual signals and / or combined signals is possible because the signals are polyploids. The ability to correctly distinguish between two groups with different copy numbers, such as a group and an aneuploid group. It can be characterized by the probability of it happening. The probability can be calculated, for example, using a signal threshold. It is characterized as the probability of correctly identifying which population a variant should be assigned to. The probability is characterized by the probabilities of true positive, false positive, true negative, and / or false negative. It is possible. The probability based on individual signals is the individual probability. Combining two signals... The probability of using a function is the join probability. For example, the probability of a truly positive aneuploid call is: Based on the criteria for a positive call using a combination of two signals, aneuploids This is the probability of being accurately identified as an aneuploid, as demonstrated elsewhere in this specification. , using allele balance signals and read depth signals in combination. Therefore, generally, the combined probability of true positive and / or true negative is higher compared to the individual probabilities. It may provide and / or more accurate results compared to individual probabilities of false positives and / or false negatives. It may offer a low connection probability.
[0084] The ability of a threshold to sufficiently distinguish between two groups (e.g., ploidy versus aneuploidy) is relevant to the art. As is well known, this can be established using receiver operating characteristics (ROC) analysis. The area under the ROC curve is used to distinguish between two groups using signals, regardless of a specific threshold. It can provide a measure of the quality of use. To draw an ROC curve, the discrimination threshold is The true positive rate (TPR) and false positive rate (FPR) are determined as they change continuously. A complete test to distinguish between the two groups has an area under the ROC curve of 1.0 and is randomized. The test area is 0.5. Preferably, the signal is greater than 0.5, preferably At least 0.6, more preferably 0.7, even more preferably 0.75, and even more Preferably at least 0.8, more preferably at least 0.9, most preferably It provides an ROC curve area of at least 0.95.
[0085] To provide an acceptable level of sensitivity (true positive rate) and specificity (true negative rate), A specific threshold may be selected. For example, the threshold may be set so that the false positive rate is approximately equal to the false negative rate. Such thresholds can be selected, for example, for ploidy (or non-aneuploidy). An aneuploidy (or a specific aneuploidy state) when it is offset against the average signal level. It can be assumed that the threshold is half of the average signal level. In some cases, the threshold is 0 Greater than 0.5, preferably at least 0.6, more preferably at least 0.7, and further More preferably at least 0.8, even more preferably at least 0.9, most preferably The threshold can be chosen to provide a specificity of at least 0.95. According to some circumstances, The value is greater than 0.5, preferably at least 0.6, and more preferably at least 0.7. More preferably at least 0.8, even more preferably at least 0.9, It may also be preferably selected to provide a sensitivity of at least 0.95. If so, the threshold is an odds ratio different from 1, preferably at least about 2 or less, or at least about 0.5. More preferably, at least about 3 or less, or about 0.33 or less, and even more preferably less At least about 4 or about 0.25 or less, more preferably at least about 5 or To provide a value of approximately 0.2 or less, most preferably at least approximately 10 or less, or approximately 0.1 or less. It can be selected.
[0086] A specific threshold is independently selected from one of the two populations that the threshold distinguishes. It is possible. For example, the threshold for distinguishing an aneuploid variant from a polyploid variant is positive. Specific percentiles of a polyploid population, e.g., the 60th percentile, the 70th percentile 80th percentile, 90th percentile, 95th percentile, 99th percentile (Assuming that the anomalous signal should be larger than the polyploid signal) This can be determined, and this can be established based on an acceptable level of false positives. Alternatively, the threshold The values are specific percentiles of an aneuploidy population, e.g., the 1st percentile, the 5th percentile. 10th percentile, 20th percentile, 30th percentile, 40th percentile (Assuming that the anomalous signal should be larger than the polyploid signal) This can be determined, and this can be established based on an acceptable level of false negatives. Some examples So, if there is more data available to characterize the set of euploids, Number-field signals can be used to establish thresholds.
[0087] The population described herein may be any population of measurements. Preferably, the population is This could be a group of measurements obtained from the same sequencing experiment on the same genetic material. By defining it in this way, noise within the group can be minimized. Such a group is This may include measurements across different loci that share the same ploidy state. However, The group underwent different sequencing experiments on the same sample of genetic material, and different samples of the same genetic material. In contrast to different sequencing experiments and / or different genetic material (e.g., different genomes) It may be defined to refer to or include measurements from different sequencing experiments.
[0088] In various embodiments, the baseline signal should be used to identify potential aneuploids. It can be established from the same sequencing data. For example, a baseline signal (e.g., mean signal) The Gunal values are one or more known or confirmed to be in the field of euploidy. Potential aneuploidy can be established based on signal measurements for a number of chromosomal segments. The signals to other segments of the chromosome being examined for body identification are as follows: As described elsewhere, this baseline signal may be offset. By doing so, it becomes easier to compare different signal types.
[0089] In some cases, it can be assumed that the population follows a normal distribution. The characteristics include the mean signal value for the population, and optionally, noise or variance / standard within the population. It can be computationally established from the scale of deviation. Two groups (e.g., the group of regular polyploids and the group of anonyms) The groups can be estimated to have roughly the same variance / standard deviation, as can be seen elsewhere in this specification. As described, the theoretical characterization of groups can be simplified. In particular, if two groups (for example) If determined from the same sequencing experiment (for different segments of a chromosome), each sig It can be assumed that the noise within the null is essentially the same.
[0090] According to some embodiments, allele balance signals and read depth signals The leads can be obtained from the same sequencing experiment. In other words, leads from a single experiment can be referenced. Variants in the genetic code can be mapped, and different alleles exist for the same variant. The relative number of reads mapped to is used to obtain the allele balance signal. In contrast to obtaining the total number of reads mapped to a specific variant (optionally, from the experiment), (Normalized to the total number of reads) can be used to obtain the read depth signal. In various applications, both signals are used as described elsewhere in this specification. It is obtained from the sequencing of extracellular DNA. According to other embodiments, allelic balance The depth signals of the Gnar and Read can be obtained from different sequencing experiments. Row determination experiments can be performed on samples of the same genetic material or samples of different genetic material. When such samples are used, the genetic material comes from the same source (e.g., extracellular DNA), or obtained from different sources (e.g., extracellular DNA versus intracellular DNA or different cell types) Allele balance signals and / or read depth signals can be detected in cellular DNA. In situations where it is obtained from, the source of the genetic material (specific sample and / or cell type) is this As described elsewhere in the specification, and used for any non-error propagation phase determination They may be the same, or they may be different.
[0091] Purpose Various latent methods for determining the ploidy state of a sample of genetic material (e.g., a genome) It can be used for various purposes. It can facilitate subsequent decisions and / or further analysis or action. Some specific ways in which such decisions can be used Non-exclusive examples are provided herein.
[0092] Genetically profiling tumors with chromosomal instability Genomic instability in tumor cells often leads to poor patient outcomes and targeted cancer therapies. It is associated with resistance to environmental exposure to carcinogens and / or random cellular events. The accumulation of genetic and epigenetic lesions, as answered, is often related to the cell cycle and DNA replication. It has the inactivation of tumor suppressor genes, which play a crucial role in production and maintenance of DNA repair. Loss or inhibition of cellular DNA repair mechanisms often leads to increased mutational load and genotypes. It causes instability. CNV is widespread across many types of cancer and contributes to disease progression. and acquisition of oncogenes and / or loss of tumor suppressors related to treatment response or resistance. This can cause genomic instability, which is associated with subclonal heterogeneity and differs between lesions. It is frequently observed in solid tumors, within the same tumor, and even within the same solid biopsy site. The heterogeneity of tumor cells, such as that described above, complicates therapeutic interventions designed around a single molecular target. This is possible. To characterize genomic instability, a genome-wide CNV profile While it is possible to use this method, the evaluation of genomic instability in bulk tumors or biopsies is necessary. Due to the availability of the sample and noise arising from contamination of the surrounding tissue or tumor heterogeneity, multiple It can become messy. Tumors with increased genomic instability, for example, platinum-based chemotherapy It has been shown to respond to certain types of treatment, including PARP inhibitors. For example, The entire text is incorporated herein by reference to Greene et al., PLoS. One.2016 Nov 16;11(11):e0165089(doi:10.1 See 371 / journal.pone.0165089.
[0093] Poly-ADP-ribose polymerase (P) is a nuclear enzyme found in almost all eukaryotic cells. ARP is a nuclear acceptor derived from nicotinamide adenine dinucleotide (NAD+). It catalyzes the transfer of ADP-ribose units to proteins, and the linear and fractional chains bound to proteins. It is responsible for the formation of branched-chain homo-ADP-ribose polymers. PARP activation and the resulting The formation of poly(ADP-ribose) is caused by chemotherapy, ionizing radiation, and oxygen free radicals. Alternatively, it can be induced by DNA strand breaks after exposure to nitric oxide (NO). Some cancers are more dependent on PARP than normal cells, and PARP is a specific cancer treatment. Regardless of the patient's response, PARP is an attractive target for cancer treatment. Furthermore, PARP is used in radiation therapy. Alternatively, it may be associated with the repair of DNA strand breaks in response to DNA damage caused by chemotherapy. Therefore, it can contribute to resistance that often occurs to various types of cancer treatments. Consequently, inhibiting PARP can delay intracellular DNA repair and enhance the antitumor effect of cancer treatments. In fact, in vitro and in vivo data show that many PARP inhibitors are ionizing or It has been shown to enhance the effects of cytotoxic drugs such as DNA methylating agents. The family of enzymes is extensive, and competitive inhibitors of PARP are known. Approved PARP P inhibitors include olaparib (Lynparza®, AstraZeneca) ;Rucaparib (Rubraca®, Clovis Oncology); Chives Paribs (Zejula®, Tesaro); and thalassoparibs (Talze Includes nna(registered trademark), Pfizer). Other PARP inhibitors being studied include These are Berryparib (ABT-888, AbbVie), Pamiparib (BGB-290) (B eiGene, Inc.);CEP 9722(Cephalon);E7016(Ei It contains sai and 3-aminobenzamide.
[0094] Platinum-based chemotherapy agents (unofficially called "platin" or "platin") are antineoplastic drugs. Tin, oxaliplatin and carboplatin, as well as several proposed drugs under development It is a platinum coordination complex containing a drug. Platinum-based chemotherapeutic agents are used for DNA repair and / or These are single adducts, interchain crosslinks, intrachain crosslinks, or DNA protein crosslinks that inhibit DNA synthesis. This causes DNA crosslinking.
[0095] Other forms of treatment suitable for cancers exhibiting chromosomal instability are understood in the art. Therefore, the methods described herein exhibit chromosomal instability and, consequently, genetic mechanisms. Targeting the structure (for example, the structure of DNA so that damaged DNA can be targeted more effectively) Suitable for a class of therapeutic drugs (that inhibit repair), gene signatures in cancer patients This may relate to identifying the agonist (ag) of a specific type of cancer. These therapeutic agents are agonists (ag) for a specific type of cancer. (Nostic) may be. Therefore, the methods described herein are for the diagnosis of certain cancers. Before or concurrently with a tissue biopsy, or prior to a biopsy, a person has been diagnosed with cancer or has cancer. This may then be performed on the suspected subject. Advantageously, the method described herein is blood sampling. This can be done based on genetic material exclusively obtained from non-invasive or minimally invasive procedures such as the following. The genetic analyses described herein apply to the same or different biological samples collected at the same time. Based on this, it may be performed concurrently with other routine analyses and / or cancer diagnosis or evaluation.
[0096] According to a particular aspect of the present invention, allele balance (used in combination) The depth signals of the reads and / or the signal of the genetic material sample taken from the subject. The signal can be obtained from extracellular DN containing or suspected to contain ctDNA. It can be obtained from A. The signal can be obtained from cellular DNA such as tumor tissue. If a propeller balance signal is used, the true signal is described elsewhere in this specification. To achieve this, non-error-transfer phase determination techniques are used to correct allele balance signals. This can be determined by the following. Non-error transfer phase determination techniques can be performed on cellular DNA. Cellular DNA can be obtained from blood cells (e.g., white blood cells). One example of a polyploid state is... Alternatively, multiple signals are obtained from cellular DNA, and non-error propagation phase determination is performed against cellular DNA. According to some aspects of the process, the same source of cellular DNA can be used for both. In some embodiments, extracellular access is required to obtain the genetic signal of the ploidy state. The DNA and cellular DNA used for determining the non-error transfer phase are from the same biological sample (e.g., Obtained from blood samples. Evaluates the ploidy status of the DNA being assessed (e.g., extracellular DNA). To do this, the ploidy state can be determined from one or more signals. The determination is made by As described elsewhere in the specification, the reference genetic code (e.g., the normal cell genetic code) This can be done in relation to the ploidy status, which is determined for one or more chromosomal segments. Detection of one or more chromosomal segments exhibiting CNV indicates chromosomal instability. It can be used to identify one or more regions of the genome. Identification of such regions This includes treatment with PARP inhibitors and / or platinum-based chemotherapy agents, etc., for chromosomal abnormalities. It can be used to indicate the presence of tumors that are sensitive to treatment with therapeutic agents that utilize stability. In some cases, the determination of the polyploidy status is (for example, administering treatment in vivo) Used to treat the subject (by means of). According to some aspects of the present invention, polyploidy The determination of the state is used to treat one or more cells in vitro. Multiple cells may include cancer cells. Cells may have cancer or be suspected of having cancer. The cells may be cultured from the subject (for example, grown from a tumor biopsy). It may include cells derived from cancer cell lines (for example, cells artificially induced to replicate cancer cells). Cells may contain a mixture of normal and cancerous cells.
[0097] De novo or hereditary CNV detection The methods described herein modify the polyploidy state (e.g., CNV) in the subject. It can be used to detect motion. According to some aspects of the present invention, (for example, in combination The allele balance signal and / or read depth signal (used in conjunction with each other) , can be obtained from a sample of genetic material taken from the subject. One or more signals are, It can be obtained from extracellular DNA. One or more signals can be obtained from cellular DNA. When allele balance signals are used, the true signal is found elsewhere in this specification. As described, non-error transmission phase determination techniques are used to supplement allele balance signals. This can be determined by correction. Non-error transfer phase determination techniques are performed on cellular DNA. It is possible that one or more signals indicating a ploidy state are obtained from the cellular DNA, and that there are no errors. According to several aspects of propagation phase determination performed on cellular DNA, the same supply of cellular DNA The source can be used for both. Cellular DNA can be from blood cells (e.g., white blood cells) or non- It can be obtained from other cells harvested by invasive or minimally invasive techniques. In the application method, extracellular DNA and non-erroneous DNA are used to obtain the genetic signal of the ploidy state. The cellular DNA used to determine the propagation phase is obtained from the same biological sample (e.g., blood sample). To evaluate the ploidy status of the DNA being assessed, one or more signals are used. The ploidy status can be determined. The same gene exhibits aneuploidy in one of its chromosomal homologs. To identify the difference in copy numbers between variants of a constellation, (for example, used in combination) Allele balance and / or read depth may be used.
[0098] The methods described herein are for the inherited variation of polyploidy. The ploidy status of each chromosome homolog is inherited from the parent, one of the target chromosomes or Variation in ploidy status at multiple loci) or de novo variation in ploidy status (i.e., A chromosomal homolog or haplotype is inherited from the corresponding chromosomal homolog of the parent from which it was inherited. (This refers to a change in the ploidy status of one chromosome in question, relative to the ploidy status of a haplotype.) It can be used to detect ploidy. The ploidy state detected in the object is compared to it. To provide a reference genetic code that can be used, hereditary haplotypes can be used. Yes, if aneuploidy exists in the genetic code of either parent, then aneuploidy is inherited. It can be determined. If aneuploidy is not present in the genetic code of either parent, then aneuploidy This can be called a de novo fluctuation.
[0099] According to some aspects of the present invention, the determination of the parent of the origin of a haplotype having an aneuploidy state. Such decisions are made, for example, variant phase determination and mother / father copy determination. This may be possible based on the prior probability of the numbers. To confirm the decision, one of the parents (the origin) Additional sequencing may be performed on the parent or both. For example, whole-genome sequencing (for example) Then, a shotgun sequence determination can be performed on both parents, which will determine the origin. This may allow you to check the corresponding number of copies in the parent file.
[0100] According to a particular aspect of the present invention, the subject may be an embryo or fetus. In this context, "embryo" refers to the stages of development from embryonic development to fetal development, including the zygote, morula, and undifferentiated embryo. It can refer to a cell organism produced by sexual reproduction, including a sac. An embryo is an in vitro (for example) (for the purpose of IVF) or may be present in the uterus. When used herein, "fetal A "child" is a child produced through sexual reproduction and present in the womb, but is no longer born. It can refer to an unborn child whose development has begun at a stage that cannot be characterized as an embryo. The subject is considered to be either an embryo or a fetus from the single-cell stage until the fetus is born. It is possible. In humans, a child is usually considered a fetus about 8 weeks after conception. What kind Is it possible to effectively obtain genetic material from an embryo or fetus, and how to do so? The technology and its inherent risks are well understood within this field.
[0101] The determination of the ploidy status of a fetal embryo (including the de novo change call) is generally based on the original As described elsewhere in the document (for example, for newborn offspring or adult individuals) ) This can be done. However, de novo detection in unborn subjects presents certain difficulties. This can be presented. For example, if cellular DNA for performing non-error transfer phase determination is readily available It may not be possible. For example, when collecting bodily fluid samples such as blood samples containing circulating blood cells. Depending on the stage of development, this may be unrealistic or impossible. Furthermore, generally speaking... Taking cellular material from an embryo or fetus carries risks to the subject's viability or health. It can lead to a miscarriage (for example). According to some perspectives, cellular DNA is involved in this process. As is well known in the field, it can be obtained from an embryo or fetus biopsy. In a preferred embodiment for determining the numerical state, one or more genetic relatives, such as the mother, are involved. Non-error-transfer phase determination can be performed on samples taken from and / or the father. DNA is obtained, for example, from a genetically close relative, as described elsewhere in this specification. Obtained from a sample of a body fluid (e.g., blood) or other tissue type, and the phase of the reference genetic code It can be used to correct the condition. Extracellular DNA is taken from a genetically close relative as needed. It may be taken. In some embodiments, the reference genetic code is known in the art. Sea urchin, at least partially, sequencing of one or more genetically related individuals (e.g., whole genome) It can be constructed based on shotgun sequencing. For example, Kitzman et al. .,Sci Transl Med.2012 Jun 6;4(137):137ra See 76 (doi:10.1126 / scitranslmed.3004323) For example, analyzing the genomes of genetically related individuals can provide a basis for subsequent analysis of the subject. The riant can be identified. Extracellular DNA derived from the embryo or fetus of the subject is known in the art. It can be collected for analysis according to any appropriate method. For example, until it is fully developed. cffDNA can be collected from the blood of the target fetus or the mother carrying the target embryo. Extracellular DNA is obtained from the blastocoel fluid of an embryo or from an embryo for IVF, as is well known in the art. Extracellular DNA of a fetus or embryo can be obtained from the cell culture medium used for culturing. This is at least partially (e.g., via whole-genome shotgun sequencing) the target genome To determine Nom and / or establish a reference genetic code for polyploidy state calls It can be used for this purpose. For example, Kitzman et al., Sci Transl Med.2012 Jun 6;4(137):137ra76(doi:10.11 See 26 / scitranslmed.3004323). Distribution of extracellular DNA Column determination is at least in part (e.g., via molecular techniques known in the art) It can be used to determine the genome or the phase of the reference genetic code of one or more genetic factors. The array of relatives and / or group reference panels is (for phase determination by non-error-propagating phase determination techniques) To provide a genome that is at least partially phased (before any correction), extracellular D It can be used in combination with NA sequencing. Extracellular data collected from embryo or fetal subjects. DNA is used to produce ploidy state calls, as described elsewhere in this specification. It can generate allele frequency signals and / or read depth signals. It can be used for the following purposes. Allele frequency signals are used for one or more genetically related individuals of a subject. This can be corrected using non-error transfer phase determination techniques performed on cellular DNA.
[0102] Examples of specific associations between aneuploidy (e.g., CNV or whole-chromosome abnormalities) and disease include the following: This is well known in the field of medicine. According to some aspects of the present invention, the determination of the ploidy state is performed in IVF. It may be used to provide information regarding decisions concerning. The methods described herein are This can be performed on a single embryo or on multiple embryos (e.g., multiple embryo candidates for implantation). It is possible. Determining the ploidy status is necessary to select one or more embryos for implantation. It may be used to select one or more embryos for keeping / or discarding / disposing of. The determination of ploidy status is (if embryos are selected for potential implantation in the future) Either the embryo is not the primary candidate for implantation but is not to be discarded. (In this context) it can be used to select one or more embryos for freezing. For example, staining Detection of aneuploidy status in chromosomes or chromosomal segments (e.g., CNV, particularly in relation to disease) Determining disease risk based at least in part on the identification of known associated CNVs. However, this can be done on the embryo. In some embodiments, identified aneuploidy (e.g., Embryos that do not have CNV (Cellular Numerical Value) may be selected for implantation or freezing. In some embodiments In this context, the embryo is determined entirely or at least partially based on the identification of aneuploidy (e.g., CN They can be ranked (by the number of Vs and / or the presence of certain CNVs). The determination of the ploidy status by the method described herein is, as is well known in the art, independently, or It can be used in combination with existing methods of preimplantation genetic testing (PGT).
[0103] According to some aspects of the present invention, the determination of the ploidy state is particularly relevant when the subject is a fetus. It can be used to provide information about decisions regarding pregnancy. For example, whether to continue the pregnancy. The decision to proceed or terminate will be as set forth elsewhere in this specification, IV The determination of ploidy status (e.g., identification of aneuploidy) is made in the same manner as the determination of F. The determination of the ploidy status by the method described herein is well known in the art. Thus, it can be used independently or in combination with existing methods of prenatal diagnosis.
[0104] According to one aspect of the present invention, the determination of the ploidy state is further tested and / or diagnosed by It can be used to provide information about the law. For example, if aneuploidy is identified, additional PGD or prenatal diagnostic testing may be recommended. In some cases, additional testing may be performed to detect It may be specific to one or more diseases associated with the aneuploidy. In some cases In particular, if the subject is an embryo or fetus, more invasive procedures may be performed on the subject. For example, to perform cell DNA sequencing or other diagnostics on cellular material, embryos Alternatively, a direct tissue biopsy may be performed on the fetus. Karyotype analysis may be performed on the subject. In some embodiments, further testing is performed substantially simultaneously with the determination of the polyploidy state (development). This can be done at roughly the same level. In some embodiments, additional testing is postponed. It may be carried out according to a schedule, (for example, for embryo-to-fetus development and / or I Allows further development to occur (after embryo implantation via VF). Several implementations In this state, based on the determination of the ploidy status when the subject was an embryo and / or fetus Therefore, additional tests may be conducted on the subjects who were born (for example, infants or children). ru.
[0105] According to one aspect of the present invention, the determination of the ploidy state is related to information regarding the decision on treatment for the subject. It can be used to provide information. For example, once aneuploidy is identified, the object is related to aneuploidy. Treatment may be given for the disease or symptoms. Treatment is any treatment appropriate to the developmental stage of the subject. This may include, for example, gene editing being performed on the embryo and / or prenatal treatment being performed on the fetus. It may be administered to the child (or to the mother with a fetus). In some embodiments, the procedure is postponed. It may be carried out according to a set schedule, (for example, for embryonic to fetal development, and / or This allows further development to occur (after embryo implantation via IVF). In the application method, the determination of ploidy status was performed when the subject was an embryo and / or fetus. Based on this, treatment may be administered to the newborn (e.g., infants or young children). Early detection of aneuploidy (for example, while present in the womb) is important in infants and children. This could allow for earlier intervention, which could lead to improved outcomes.
[0106] Disease Diagnosis Based on known associations with diseases such as aneuploidy (e.g., CNV), as described elsewhere in this specification. In addition to the diagnostic methods described herein, the methods described herein identify novel associations between aneuploidy and disease. It can be used to do so within a group of subjects with a specific disease or predisposition to the disease. By identifying the same aneuploidy, an association between aneuploidy and disease can be established.
[0107] In particular, to elucidate the function of SNPs in relation to disease, one or more rare aneuploids The use of the phase determined by the non-error-propagating phase determination of the variant, and (for example, the same hap Within the block or by the method described herein, in the same phase alignment Adjacent phases (within a set of two phases that have been determined to be related to the disease) The identification of SNPs can be used. Rare variants and identified SNPs are linked. It can be determined that it is in chain disequilibrium. (For example, other SNPs that are in linkage disequilibrium with the identified SNP.) Compared to adjacent SNPs, the SNP's (for example, its polygenic risk score (PRS)) By increasing their contribution to disease risk (in which case), rare variants were identified. It can be effectively associated with SNPs. Therefore, rare Varian can be associated with more common SNPs. Since the chaining of SNPs is related to disease predisposition, it can improve the predictive power of more general SNPs. can.
[0108] Once disease-related aneuploidy variants are identified, diagnostic criteria for predisposing to the disease are used. For the purpose of the target, sequencing may be performed on other subjects. Sequencing may involve aneuploidy variants. It may be targeted for capture. Sequencing is as described elsewhere in this specification. , (for example, via a microarray) it is determined to be an aneuploid variant and chain disequilibrium. Sequencing may be performed to target adjacent SNPs, such as adjacent SNPs. Aneuploidy variants (e.g., rare variants) and SNPs (e.g., common SNPs) This can be done to target both.
[0109] The diagnosis of the disease is at least partially based on the presence of one or more aneuploid variants. Based on non-existence, and / or at least partially, one or more anomalous fields This is done based on one or more SNPs that have been determined to be in linkage disequilibrium with the variant. To obtain. As is well known in the art, diagnosis can be made based on, for example, PRS. The appropriate course of action may be determined based on information provided for any of the diagnostic methods described herein. For example, the subject is diagnosed with, has, or has developed a condition. Treatment (preventive measures) is provided for diseases diagnosed with at least an increased predisposition to the condition. (May include) Diagnosis and treatment may be based on other clinical factors as understood in the art. This can be done in combination with children and variables.
[0110] Determining the phase of germline mosaic variants The method described herein relates to the haplogroup in diseased individuals having an aneuploid variant. It can be used to identify the pus. Gametes from affected individuals can be used for IVF purposes (e.g.) For example, it may be screened to avoid gametes with an identified haplotype. ru.
[0111] According to one aspect of the present invention, the use of non-error-transfer phase determination techniques in the reproductive system of affected individuals This can be applied to determine the phase of a column mosaic variant. Such affected individuals This may include, for example, individuals with Noonan syndrome or rhasopathy. The information provided is, as described elsewhere in this specification, information regarding decisions about IVF. It can be used to provide information. For example, the phase-determined information can be used for IVF and PG. Used to determine which haplotypes should be avoided in subsequent generations using T. It is possible.
[0112] According to one aspect of the present invention, a rare variant in each of the two parents is a common variant. It is then associated with a rian (e.g., SNP), and subsequently, which SNP is inherited in the embryo. After determining the trait, the inheritance of that rare variant in the embryo is inferred. Long phase-determined reads are used to include predictions of rare variants in the genome. It is possible. [Examples]
[0113] [Example 1] To simulate chromosomal imbalance (amplification) on human chromosome 21, a specific haplogroup is used. A dataset of synthetic reads corresponding to each type was generated from the phase-determined genome. To the effect of reference, Samadian et al. are incorporated herein by reference in their entirety. al.,PLoS Comput Biol.2018 Mar 28;14(3):e 1006080(doi:10.1371 / journal.pcbi.1006080 ) Follow the method described in ) 10XGENOMICS® synthetic length readout Data created using Approach (a CHROMIUM® product) Lee from nucleotide positions 30227447~44327015 of sample NA12878 Added a do. The input to this software has a phase shift error at approximately 37Mb. It included a phase-determined VCF file and a sequence determination file (bam). Next Then, 200,000 of these reads were obtained from standard genome repositories from 1,000 genome repositories. Added to the set of shotgun leads. Platinum for sample NA12878 Based on the Genomes variant set, the position predicted to be "0|1" is "A Assign a haplotype, and assign the haplotype "B" to the position predicted to be "1|0". Assigned. For example, the entirety of which is incorporated herein by reference is Eberle e t al.,Genome Res.2017 Jan;27(1):157-164( See doi:10.1101 / gr.210500.116). (More than 5 reads) For depths exceeding 20 reads, the location was filtered. Based on the phase determination of the phase-determined VCF file, each position is assigned to the "A" allele or The "B" allele was assigned. Figure 1 shows the dataset of synthetic reads for chromosomes. Regarding heterozygous sites (SNPs), the allele balance is adjusted to the proportion of the A allele. To show.
[0114] As shown in Figure 2, the signal-to-noise ratio of the allele balance signal is improved. Therefore, consecutive SNs on the same haplotype as determined by dilution pool sequencing P is binned, and the allele balance signal is averaged across the binned regions. Figure 3 shows the allele balance across the 300Kb window of the haplotype block. The signals were averaged. From the averaged allele balance signals in Figures 2 and 3... As is clear, chromosome amplification of the A haplogroup, specifically from about 30 Mb to 37 Mb Chromosomal deletion of the A haplogroup immediately following trisomy, specifically from around 37 Mb to 4 It appears that there are two distinct types of aneuploidy that could be present in monosomy up to approximately 4 Mb. The haplotype blocks determined from dilution pool sequencing across the aneuploidy region are shown below in Figure 3. This is illustrated in the section.
[0115] Data obtained from Hi-C experiments on sample NA12878 are shown in staging.4. dnucleome.org / filesprocessed / 4DNFIY9YBG6 Downloaded from I / . The Hi-C data was phase-determined as described below. In VCF, identify the switch error and then call the anomalous case accurately. It could be used to correct the gene balance data. Since the reference is HG38... The vcf file was mapped to hg38. (Tool from the program HapCut2) The entirety of "extractHAIRS" is incorporated herein by reference. Edge et al., Genome Res. 2017 May;27(5): As described in 801-812 (doi:10.1101 / gr.213462.116) As such, we generated fragments of evidence supporting various combinations of phase blocks.
[0116] Using Hi-C data, the phase alignment of two phase sets was evaluated. This set is a set of SNPs that exist at a location of approximately 30Mb to 37Mb. The second phase set is defined as the SNPs on chromosome 21 from approximately 37 Mb onwards. Defined as the remainder. Information-providing reads (two or more overlapping heterojunction variants) Hi-C fragments containing ) are self-consistent across subgroups. They can be grouped into sparse subgroups. As shown in Figure 4, both sets of phases and at least Partially overlapping subgroups (i.e., at least one from each of the two sets of phases) Further filtering of the Hi-C data to select subgroups (those with one SNP) and evaluation. And overlapping subgroups are exact matches (i.e., "00", "000", "000") It does not have a mismatched haplotype call, such as "0" or mismatched (i.e., "01 It has at least one mismatched haplotype call, such as "011" or "0111". It was determined that it was either ( ) or ( ). Distribution of perfectly matching and mismatched fragments. The total number of subgroups including this is shown in the table. As shown in Figure 4, there are a total of 20 subgroups. There were cases where the results were inconsistent with the diluted pool sequencing, and 1 case was inconsistent with the diluted pool sequencing. They matched. The number of fragments represents the number of fragment reads within each subgroup, and each fragment is a haplota Having at least two of the SNPs that support ipucol, but not necessarily subgroups It is not guaranteed that each of the SNPs within is present. Observed concordant and inconsistent measurements To evaluate the distribution, the probability of obtaining concordant and inconsistent measurements is equal. Assuming that the observed distribution occurred purely by chance, we calculated the probability using the binomial distribution. The binomial probability is extremely low, and the probability of a skewed distribution occurring purely by chance is less than 0.01%. Therefore, the estimated phase alignment between the two sets of phases is not actually correct. Or, because they were misaligned, the Hi-C measurement results that overlap with the two sets of phases are mainly inaccurate. It was determined to be a match. The first phase set (spanning approximately 30Mb to 37Mb) The phase determination of the first phase is correct, and the phase determination of the second phase set (from 37Mb onwards) is correct for the two phase sets. Assuming that the nature of the switch error introduced in between is incorrect, the second phase set The phases are reversed, and the true pair is averaged across the 300Kb window of the haplotype block. The true allele balance signal was corrected as shown in Figure 5. The signal shows a 14Mb aneuploidy at approximately 30Mb to 44Mb, This can theoretically correspond to the amplification of haplotype A or the deletion of haplotype B.
[0117] [Example 2] The simulated dataset from Example 1 was replicated, but aneuploidy on chromosome 21 was found. Reads corresponding to sex (amplification of haplotype A) were downsampled to approximately 9% of the measured cells. The ring indicates that approximately 91% of the cells exhibit euploidy across the same chromosomal segment. Figure 6A shows Regarding the 30.3Mb-37Mb portion of the chromosome corresponding to the heterozygous gene locus (SNP) This shows the raw allele balance signal. The formula has a mean of 0.5232 and a standard deviation of 0.1141. Figure 6B shows the diluted pool. Averaged across a 300Kb window of the haplotype block determined by sequence determination. The same allele balance signal is shown. As is clear from Figure 6B, 9% aneuploidy Allele balance shifts introduced by somatic cells are more easily identifiable and mark The criterion has decreased to 0.0258 as a result of bin splitting. Therefore, this embodiment is This demonstrates the ability to call amplification even at low allele ratios.
[0118] [Example 3] In this example, as schematically shown in Figure 7, the disomy (D) measurement values are Trisomy (
number
number
number
[0119] The total probability of disomy is equal to the total probability of trisomy (i.e.,
number
number
number
[0120] Next, using X1 as follows, we can determine false positives (i.e., disomy) from the cumulative distribution function. We calculated the probability of signal X1 corresponding to (mistakenly characterizing this as trisomy).
number
[0121] Two signals - X1, read depth signal and independent signal X2 (for example, Disomy / trisomy is called by using allele balance signals together. The method for performing this was computationally simulated according to the call scheme shown in Table 1 below. .
[0122] [Table 1]
[0123] As described above, the same assumptions made for the distribution of signal X1 apply to signal X2. The analysis was performed on the distribution. False positives were called based on the use of both distributions according to Table 1. The probability of calling and the probability of not calling at all are determined in Table 2 as follows, where "n "ormcdf" is a normal cumulative distribution (for example, in MATLAB®). It is a function.
[0124] [Table 2]
[0125] Assuming m1=6 and m2=6 / sqrt(3), the probability values are calculated as follows. Reta:P FPX1 =0.0013;P FPX2 =0.0416; and P FPX1X2 = 0.000056.
[0126] [Example 4] Population of disomy (D) measurements and trisomy
number
number
number
[0127] Here too, the total probability of disomy is equal to the total probability of trisomy (i.e.,
number
number
number
number
[0128] Next, the false positive rate was evaluated by integrating the joint probability function as follows.
number
number
number
[0129] Next, X2 was solved as follows:
number
[0130] Therefore, the false positive rate is
number
[0131] Next, the false positive rate is empirically calculated using the following MATLAB® code. It is possible to do this, where "sum" is the difference between the signal mean m1 and m2. This is the false positive rate. %variables n=2000; m1=6; m2 = 6 / sqrt(3); lim=20; delta = 2 * lim / (n-1); x1_vec=[-lim:delta:lim]; x2_vec=[-lim:delta:lim]; sum=0; for x1=x1_vec ind=find(x2_vec>(m1^2+m2^2-2*m1*x1) / (2* m2)); for x2=x2_vec(ind) sum=sum+exp(-0.5*(x1^2+x2^2))*delta^2 / ( 2*pi); end end sum
[0132] The simulation was performed using the same signal average as in Example 3. Here, "sum" This combination combines the signal average m1 with a slightly weaker signal average m2. This corresponds to the probability of observing a false positive in a rate scenario. The probability of a false positive is P(false positive) = While sum was determined to be 0.00026, the individual (evaluated in Example 3) The probability was determined to be higher:P FPX1 =0.0013 and P FPX2 =0.04 16.
[0133] The simulation involves two signals, one of which has a variance three times higher than the other. By combining the independent signals, you can use any one of the signals individually. Compared to that, it has been demonstrated that the false positive rate can be reduced by at least five times.
[0134] [Example 5] In the same manner as in Example 1, a mixture of synthetic aneuploid DNA was placed on chromosome 21 at 30.3M The fabrication was performed using amplification starting from position b. Figure 8A shows the position from 31Mb to 37Mb. Figure 8B shows the depth signal of the reads, and the bin division for the 31Mb–37Mb location. The histogram of the depth measurements of the reads is shown. Similarly, Figure 9A shows the 31Mb~3 Figure 9B shows the allele balance signal at the 7Mb position, and 31Mb~37M A histogram of binned allele balance measurements for position b is shown. Figure 9C shows a histogram of the binned allele balance measurements, where the measurements are: The results were averaged across 50 adjacent SNPs.
[0135] The average signal-to-noise ratio is incorporated herein by reference in its entirety, 2014. U.S. Patent No. 8,682,592 by Rabinowitz et al., issued on March 25th. As described, it was calculated from aggregated data. Theoretical data for Examples 3 and 4 As described in the simulation, the threshold signal value for indicating trisomy is read Average diploid signal and average triploid signal for both depth and allele balance Selected to be intermediate, and calling false negatives as in Examples 3 and 4. We approximated a scenario where the probability is equal to the probability of calling a false positive, but we would like to choose a different threshold. This can be done by calculating the average measurement over the 20Mb to 30.3Mb range. Determine the average signal for diploidy and average the measurement over the 30.3Mb–37Mb range. The average signal for triploidy was determined by calculating the value. Therefore, the threshold is For read depth and allele balance signaling, respectively, 31 per position It was determined to be a .5 lead and a 58% A (0.58).
[0136] Subtract the corresponding threshold from the signal value at each position, and then over the amplification region By normalizing the noise level by dividing by the measured standard deviation The amplification of read depth signal and allele balance across approximately 2500 measurements / positions. A signal-to-noise plot was generated for the signal. Figure 10 shows the read depth signal. Figure 11 shows a signal vs. noise plot for nal, and allele balance signal The signal-to-noise plot for the read is shown. Figure 12 shows the read depth and alleles. The integrated sig is obtained by summing the signal-to-noise values for the child balance. This indicates a null value. The mean and standard deviation of the integrated signal shown in Figure 12 are both 0. The values were calculated to be 0.4940 and 0.11.
[0137] To enable those skilled in the art to construct and use the present invention, the present invention is described and illustrated in sufficient detail. However, without departing from the spirit and scope of the present invention, various substitutions, modifications and improvements may be made. This should be obvious. The examples provided herein are representative of preferred aspects. These are illustrative examples and are not intended to limit the scope of the invention. Authors may come up with modifications and other uses in the embodiments. These modifications are part of the present invention. It is encompassed in the spirit of and defined by the claims.
[0138] Without departing from the scope and spirit of the present invention, the inventions disclosed herein may be made as follows: It will be obvious to those skilled in the art that various substitutions and modifications can be made. Such situations are not physically possible, or unless otherwise indicated by the context. It is understood that they can be combined.
[0139] All patents and publications referred to herein represent the level of those skilled in the art. The licenses and publications are as if each individual publication were incorporated by specific and individual reference. This is incorporated herein by reference to the same extent as it has been shown to be incorporated herein.
[0140] The present invention as described herein exemplifies any other invention not specifically disclosed herein. It can be properly carried out in the absence of one or more elements or one or more limitations. For example, in each example of this specification, "comprising" means "essentially from". "to become (consisting essentially of)" and "to consist of ( Any of the terms "consisting of)" can be either of the other two terms It can be replaced. The terms and expressions used are used as descriptive terms, not limiting ones. In using such terms and expressions, the characteristics or so indicated and described are not included. It is not intended to exclude some equivalents, but within the scope of the claimed invention, It is recognized that various modifications are possible. Therefore, the present invention has preferred aspects and optional aspects. Although specifically disclosed by the characteristics of the selection, changes to the concepts disclosed herein and The modifications may be used by those skilled in the art, and such changes and modifications are included in the appendix. It should be understood that this is considered to fall within the scope of the invention as defined by the claims. It is.
Claims
[Claim 1] The invention described in the specification.
